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Abstract 
 
Improved drug delivery technologies and real-time protein monitoring 
through advancements in directed evolution techniques and biosensor 
optimization 
 
by 
 
Faye Yi Fong 
 
Whereas twentieth century medical research sought treatments to benefit as 
many individuals as possible, perhaps the watchword of the next century is 
“precision medicine”, which seeks to maximize the benefit of treatment for each 
individual.  Every patient has a unique physiological and pathological profile.  The 
effective dosage of a drug, the rate of disease progression, and even the risk of 
complications are determined by genetic and lifestyle factors specific to the 
individual.  The next generation of medical innovation aims to customize healthcare 
to the unique needs of each patient.   
One area of research in precision medicine is controlled drug delivery, which 
aims to precisely supply therapeutic molecules to the correct tissue and organ 
locations at the correct times.  There is a universal general strategy: an engineered 
protective vehicle which reacts specifically to biological or physical triggers to 
release an encapsulated drug payload.  Controlled drug delivery reduces toxic side 
effects, improves efficacy, and customizes therapy to the individual.  Recently, 
 viii 
 
there has been heightened interest in the development of pH-controlled drug 
delivery.  A clinically significant pH gradient exists across the endocytosis pathway 
where the pH changes from 7.4 at the plasma membrane to 5.2 in the late 
endosome.  Endocytosis is responsible for trafficking and modifying many important 
proteins and as such, triggered activation of drugs at specific pH corresponding to 
specific modules of endocytosis is a rich area for therapeutic targeting.   
Towards these applications, we have developed an in vitro selection process 
to generate nanocarriers which switch structure in response to shifting the pH in 
order to release a drug payload.  We have also adapted our selection process to 
generate pH-controlled aptamers whose affinity for ligands can be turned on or off 
by changing the pH.  The ultimate goal is the rapid generation of useful pH-
controlled nanovehicles for customized delivery of any therapeutic payload.   
But to fulfill the promise of precision medicine, there is also a great need for 
new diagnostics which can more quickly and cost-effectively return data about the 
patient.  Currently, the standard of care for biomarker monitoring is the enzyme 
linked immunosorbent assay (ELISA).  Although ELISAs are highly accurate, they 
are time- and labor-intensive, requiring the expertise of a qualified medical lab 
technician in a centralized facility.  The best way to meet the diagnostics needs for 
precision medicine in the next century is to develop real-time sensors which are 
rapid, fully-automated, and function at the point-of-care.   
To that end, we have built a real-time electrochemical aptasensor for 
monitoring α-thrombin protein directly in human plasma.  In our devices, protein 
detection is achieved by the binding of the target protein with methylene blue-
modified aptamers, which alters the measured output current.  In parallel, the 
 ix 
 
incoming plasma sample stream is subjected to a pretreatment cocktail that blocks 
native inhibitors and prevents clot formation, thus amplifying the thrombin signal.  
Our platform could potentially be extended towards monitoring any protein of 
interest with results reported within minutes, directly at the patient’s bedside.   
Controlled drug delivery and real-time biomarker monitoring are powerful 
complementary technologies in precision medicine.  We envision the possibility of 
maximum patient benefit from therapy, where controlled drug delivery is further 
finetuned by closely monitoring the individual’s response to treatment.   
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Chapter 1. Introduction 
Since 1952, DNA has been confirmed as the genetic material[1].  The 
sequence information within it makes us what and perhaps, who we are as well.  
Since then, we have learned much about the chemical and physical properties of 
the DNA material.  In contrast to the nucleic acid RNA, DNA lacks a 2’ hydroxyl on 
its sugar group, affording it increased chemical stability as it is less susceptible to 
hydrolysis[2].  We also know that two complementary strands of DNA will hybridize 
into a double helix via Watson-Crick basepairing rules: { A-T, G-C }[3].  More 
recently, we have learned that DNA can exist in single-stranded form and can 
intramolecularly fold into interesting structures, not unlike RNA[4].  Notably, it is in 
single-stranded form that RNA has shown not only transcriptive functions, but 
recognition and catalytic functions[5].  Researchers have hypothesized and later 
confirmed that single-stranded DNA can also be designed to perform special 
functions. 
To summarize: DNA is chemically stable, can be programmed to self-
assemble, and folds into higher order structure when single-stranded.  Researchers 
have thus recognized that synthesized DNA can be developed as a next generation 
material to perform many useful tasks.  This is the story of several advancements in 
the field. 
 
1.1 DNA: a next generation material for nano-engineering 
The first explorations into DNA as a material for nanoscale engineering were 
purely structural.  Researchers designed short DNA oligonucleotide sequences 
(oligos) which would self-assemble according to Watson-Crick basepairing rules 
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into sophisticated 2D and later, 3D structures[6].  For example, a fundamental 
structural motif is the immobile Holliday junction[7].  Four 16bp oligos were designed 
to hybridize unambiguously into a specified four-armed junction[7].  Importantly, the 
sequences were designed to minimize symmetry and therefore make strand 
migration negligible[7].  That is, the strands can only assemble in one conformation: 
the first 8 basepairs of Strand 1 will only hybridize with the last 8 basepairs of 
Strand 4, and the last 8 basepairs of Strand 1 will only hybridize with the first 8 
basepairs of Strand 2[7].  It is easy to see that this DNA junction could be used to 
join larger modules for higher order structures.  The advantages of being able to 
dictate complex structures at the nanoscale were recognized by many, and since 
then, researchers have made many elaborate and whimsical objects including 
smiley faces, tetrahedrons, and three-dimensional rastered-in pyramids[8].  The field 
has creatively been termed “DNA origami” and has demonstrated that DNA has a 
rich potential to be formed into sophisticated self-assembled nanostructures.   
The next leap in DNA engineering came when it was discovered that single-
stranded oligos could be programmed to fold into structures which could act as 
recognition elements for biological molecules, analogous to antibody-antigen 
binding[9].  These valuable oligo structures are known as “aptamers”, and they were 
the first demonstration that DNA could act as a functional material[9].  In the 1990s, 
several researchers developed “Systematic evolution of ligands by exponential 
enrichment” (SELEX) to discover aptamer sequences with binding affinity for a 
variety of protein and small molecule targets[9].  Perhaps the most canonically 
important early DNA aptamers were the two α-thrombin-binding aptamers 
independently discovered by Bock et al.[10] and Tasset et al[11].  Both aptamers are 
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G-rich sequences which fold into G-quadruplex chair structures[10],[11].  Each 
aptamer has high specificity and binding affinity for α-thrombin, but at different 
binding epitopes; the Bock aptamer binds at the fibrinogen-binding site[10] and the 
Tasset aptamer binds at the heparin site[11].  These aptamers are comparable to 
traditional antibodies in their affinity for thrombin and have also been shown to 
inhibit the binding of native ligands[10],[11].  There has been continued strong interest 
in finding aptamers against other biologically significant targets, owing to the 
advantageous properties of DNA-based affinity reagents: they possess greater 
thermal stability than protein antibodies, are cheaply chemically synthesized, and 
can be readily modified with side chains and substitutions via well-established DNA 
modification chemistry[9].   
Recently, researchers have combined structural and functional DNA 
engineering to create multifunctional nanomachines.  For example, one group 
designed a collection of oligos and fuel strands which together form a “DNA 
walker”, demonstrating the generation of precise mechanical force at the 
nanoscale[12].   Researchers have also developed nanomachines which react to 
specific stimuli to perform a prescribed function.  For example, in reaction to UV 
irradiation, an azobenzene-modified DNA nanopore opens to release a drug 
payload from a mesoporous nanocontainer[13].  A DNA hydrogel has also been 
developed where the phase transition of the hydrogel material is controlled by the 
concentration of a specific analyte[14].  The hydrogel consisted of polymers modified 
with rationally designed DNA linkers which crosslink via hybridization but which also 
contain the sequence for the ATP-binding aptamer[14].  In the presence of an 
activating concentration of ATP, hybridization is disrupted and the hydrogel 
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dissolves[14].     There are countless other varieties of DNA machines including self-
reporting sensors (molecular beacons)[15] and even catalysts (DNAzymes)[16].  
Altogether, DNA possesses incredible potential as a next generation nanoscale 
engineering material and in this thesis, we will describe our efforts to develop it into 
useful nanocarriers and biosensors.   
 
1.2 Precision medicine 1: Controlled drug delivery 
The next century in medical research will be defined by the paradigm of 
“precision medicine”.  The mission of precision medicine is to develop technologies  
which more precisely diagnose and treat patients, customizing treatment to each 
individual, and thus maximizing patient benefit from therapy[17].  One of the main 
arms of this research philosophy has been the development of controlled drug 
delivery technologies.  There are several drugs currently on the market which 
represent the classical methods of controlled release.  For example, extended time 
release versions of established pharmaceuticals such as Zolpidem (sleep aid)[18] 
and Adderall (ADHD, narcolepsy treatment)[19] help patients achieve a more regular 
dosage over a longer period of time.  Other well-established forms of controlled 
delivery are prodrugs such as 5-fluorouracil (chemotherapeutic) where the 
therapeutic molecule is administered as an inactive precursor that accumulates in 
the target tissue, and is then metabolized by the body into an active form[20].  The 
purpose of these multivarious technologies for controlled release is clear: to specify 
the location and times at which active molecules are administered, thereby reducing 
side effects and improving therapeutic outcomes[21].   
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However, new and unorthodox methods for controlled drug delivery are 
urgently needed because next generation pharmaceuticals no longer fit the 
traditional pharmacokinetic profile.  Conventional medicines are small molecule 
drugs that are water soluble, pass with relative ease through the cell membrane, 
and a single therapeutic dose can be packaged into ~1 mL volume[22].  Next 
generation drugs include macromolecular assemblies such as fusion antibodies, 
nanoparticles, and gene therapy[22].  The new challenges for controlled drug 
delivery will be to package these drugs for improved bioavailability and to increase 
cellular internalization of the payload[22].   
Perhaps the most exciting and difficult challenge for controlled drug delivery 
is the realization of the promise of gene therapy.  Nucleic acid drugs for gene 
therapy face enormous transport challenges[23].  First, nucleic acids are vulnerable 
to attack by native nucleases in the blood[23].  Second, the payload must be 
targeted to the correct tissue or organ to reduce off-target toxicity[23].  Third, the 
delivery method must facilitate cellular and/or nuclear internalization of the nucleic 
acid payload, bypassing the natural size and charge exclusion of these 
membranes[23].  Currently, liposome- and nanoparticle-based schemes are being 
developed which access the cellular internalization pathway known as endocytosis 
in order to achieve drug uptake[23].   
 
1.3 Targeting the endosome: pH-triggered drug delivery 
In the first half of this thesis, we will discuss advancements we have made to 
develop endosome-targeting DNA machines for delivering a therapeutic payload.   
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Endocytosis is the process by which cells internalize materials.  Although 
there are different subtypes of endocytosis (clathrin-mediated, caveolae, 
macropinocytosis, and phagocytosis), the general process involves deformation of 
the plasma membrane for engulfment of an external object, pinching off into an 
endosome, and then transport and maturation of the endosome along various 
pathways[24].  Early endosomes receive engulfed materials from the cell surface 
including nutrients which are carried in by transport proteins[24].  Typically, the 
transport proteins will release the nutrients before being returned to the plasma 
membrane via recycling endosomes[24].  Importantly, early endosomes are 
responsible for sorting the useful engulfed materials and transporting them to other 
cellular destinations such as the Golgi body[24].  For example, the early endosome 
may traffick proteins to the Golgi for important post-translational modifications[24].   
When an early endosome has finished sorting out useful materials, they are left 
primarily with waste materials[24].  Early endosomes will mature into late 
endosomes, and finally, lysosomes, which will degrade the waste[24].  Furthermore, 
the endocytosis pathway is a highly attractive target for controlled drug delivery.   
Currently, there is great interest in developing drug delivery vehicles which 
selectively release their payload after engulfment in order to concentrate the dose 
inside the target tissue and reduce off-target side effects[25].  Additionally, due to the 
role of the endosomal network in protein trafficking, targeting therapeutics to 
specific endosomes in order to manipulate protein expression is a rich therapeutic 
opportunity[24].   
At the start of internalization, the endosome pinches off from the cell 
membrane (pH 7.4) and then matures from early endosome (pH 5.5-6.0) to late 
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endosome (pH 5.2), and finally into the lysosome (pH 4.5)[26].  Importantly, in 
Nature, the characteristic pH gradient of the endocytosis pathway is used by the 
cell to control selective transport and delivery of engulfed molecules.  The classsical 
example of this phenomenon is transferrin, a transport protein which carries Fe(III) 
into the cell[27].  At pH 7.4, transferrin strongly binds 2 molecules of Fe(III), but after 
internalization when the endosomal pH drops, transferrin’s binding affinity for Fe(III) 
is greatly decreased and the ligand is released into the cell[27].  As such, it is of 
great interest to the research community to create analogous pH-triggered drug 
delivery systems which sequester a drug payload until endosomal uptake and 
acidification activates release.   
We note that historically research in this area has focused on the 
development of polycationic polymers and nanoparticles for the delivery of 
therapeutic nucleic acids[28].  Typically, the system contains a positively charged 
component to shield the strongly negative phosphate backbone of the nucleic acid 
payload, enhancing absorption through the phospholipid membrane[28].  
Furthermore, these systems are also coupled with a mechanism for pH-triggered 
cleavage in order to release the drug payload into the acidified endosome.  For 
example, a polymeric micelle was developed where adriamycin was conjugated to 
the block copolymer via an acid-labile hydrazone linker, thus providing a 
mechanism for intracellular pH-dependent drug release[29].  Another well-
established strategy is the synthesis of polymer micelles with reversibly protonated 
amine residues which swell or shrink in response to pH change in order to deliver 
encapsulated drugs[30].   
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Owing to the many useful material properties of DNA, in particular our ability 
to program it to execute complex functions, DNA machines have seen development 
as pH-triggered drug delivery vehicles[31].  Currently, such DNA machines are based 
on a handful of well-known pH-sensitive DNA motifs.  Perhaps the most widely 
explored structure is the i-motif, a C-rich DNA sequence which contains no notable 
secondary structure at pH 7.4, but forms a stable C-quadruplex chair structure at 
pH 5.2[32].  The i-motif was first discovered as a recurring motif in telomeric DNA, 
but the role of its pH-dependent structure-switching in DNA expression is 
unknown[33].  The i-motif’s pH-reactive behavior arises from its cytosine repeats[32].  
At neutral pH, C•C mismatch basepairs are disfavored, but at low pH, protonated 
cytosines will form highly favored C•C+ basepairs, creating a stable C-quadruplex 
structure[32].  The i-motif has been used creatively for many pH-dependent release 
applications[32].  For example, a drug delivery vehicle was developed where gold 
nanoparticles were decorated with an i-motif-containing DNA linker that could be 
loaded with siRNA via partial hybridization to a complementary region on the 
linker[34].  In the presence of acidic pH, the linker preferentially folded to form the C-
quadruplex, thereby releasing the siRNA payload[34].  In another system, silica 
nanopores containing a small molecule payload were capped with i-motif DNA[35].  
In its C-quadruplex form the i-motif closes the nanopore with high efficiency, but 
when the pH is raised, the i-motif unfolds and releases the payload[35].  There are 
also other well-known pH-responsive DNA motifs such as the triplex switch[36] and 
long A•G runs[37] which have been likewise incorporated into analagous systems for 
drug delivery.   
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Our work focuses on high-throughput methods to generate novel pH-reactive 
DNA motifs using a technique known as in vitro selection.   
 
1.4 How selection works 
Systematic evolution of ligands by exponential enrichment (SELEX), also 
termed selection, is an in vitro technique to generate molecules with specific 
properties by using selective pressure and amplification to identify best performers 
from an initially diverse combinatorial library[10].  In our subfield, we focus on DNA-
based selections to find pH-controlled nanomachines.   
Traditionally, selections are performed as follows: we start with a diverse 
combinatorial library of oligonucleotide sequences typically of length 100 bp where 
a subset of the basepairs are randomized.  The library is challenged with a surface-
bound target (typically on a nitrocellulose membrane or magnetic bead)[10], [38].  The 
sequences with some affinity will associate with the surface-bound target and be 
separated out from solution[10], [38].  These partitioned sequences are then amplified 
and subjected to further rounds of selection with increasing selection stringency[10], 
[38].  The sequence pool eventually converges to a subset of high-affinity winners[10], 
[38].   
Briefly, we would like to sketch out mathematically how partitioning and 
amplification of a combinatorial pool leads to sequence convergence.  Suppose you 
start with 100 unique sequences in your combinatorial library.  Of the total 100 
sequences, let’s say that 10 of these sequences have 2X greater affinity for the 
target compared to the other 90.  If 10% of sequences are collected in a round of 
selection, you will isolate 10 sequences.  If all sequences in the starting library had 
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the same affinity for the target, the probability of being collected would be equal for 
all 100.  However, since 10 of the sequences have 2X the probability of being 
picked, this means that 2 out of the 10 isolated sequences will be good binders.  
The 10 isolated sequences are amplified ten-fold to return the pool size to 100 
sequences, where now there are 20 good binders and 80 poor binders.  If the rate 
of enrichment remains constant, the next round will contain 40% good binders, the 
round after that 80% good binders, and by the fourth round, the pool will have 
converged to 100% good binders.   
In our work, we have modified traditional selection into a “Falling-Off” SELEX 
scheme[39].  Instead of being in solution, our library is initially bound non-covalently 
to the target.  We then subject the library-target complex to pH change which will 
stimulate a conformation switch in a subset of the sequences, releasing the best 
performing pH-reactive sequences into solution.  We collect the eluent, amplify it 
and subject it to further rounds of selection.  We will show that this powerful 
combinatorial technique allows us to generate pH-active drug delivery vehicles and 
pH-controlled aptamers in high-throughput.   
 
1.5 Precision medicine 2: Real-time biomarker monitoring 
Another important arm of research in precision medicine is improving 
diagnostics.  In this area, our goals have been to increase the speed of returning 
measurements results and to reduce human labor expended when performing 
diagnostic assays.  Currently, the only FDA-approved system for rapid continuous 
molecular monitoring is glucose monitoring for diabetics[40].  Importantly, this 
technology allows diabetic patients to rapidly respond to spikes in blood glucose 
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with insulin, thus allowing more effective regulation of blood sugar and improved 
patient outcomes[40].  While nearly every aspect of medicine could be improved by 
better biosensors, there is an especially great need for better, faster biosensors in 
the emergency room.  Emergency room illnesses like traumatic injury and acute 
infection progress so quickly that regular biomarker assays (turnaround time ≥ 1 
hour) may return information which no longer accurately describes the patient’s 
condition[41].  As such, emergency room medicine until this point has depended 
mostly on symptomology and qualitative tests that do not provide molecular 
information[41].   
Coagulopathy is a common complication encountered in the emergency 
room which may benefit greatly from faster reporting diagnostics[42].  Coagulation is 
a complex process by which tissue injury stimulates a network of coagulation 
proteins producing controlled enzymatic cleavage of soluble fibrinogen into 
insoluble fibrin, which combines with platelets to form clots to close a wound[42].  
There are over twenty known procoagulation and anticoagulation factors which 
regulate this process as well as chemical crosstalk with immune system proteins[42].  
Trauma-induced coagulopathy is where traumatic injury has caused huge blood 
volume loss, changes to the blood chemistry, and inflammation, resulting in 
massive dysregulation of typical blood concentrations of coagulation factors[42].  
Traumatic injury victims are vulnerable to abnormal coagulation responses such as 
embolism (hypercoagulability) and hemmorhage (hypocoagulability) [42].   
Current diagnostics for coagulopathy rely on symptomology and qualitative 
tests because these assays can be performed relatively quickly (<1 hour).  For 
example, it is common to measure the prothrombin time (PT), where blood is drawn 
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from the patient, purified into plasma, activated by tissue factor, and the time for the 
plasma to clot is measured optically[43].  Thromboelastography (TEG) is another 
typical clinical assay where whole blood is permitted to clot around a rotating wire 
probe and the mechanical strength of the clot is measured as a function how 
strongly the clot retards rotation of the wire probe[43].  Unfortunately, these methods 
do not offer molecular information about protein and small molecule concentrations 
in the blood.  In order to obtain molecular information, clinicians currently rely on 
the enzyme-linked immunosorbent assay (ELISA) which requires an expert 
technician to perform and for which the turnaround time ranges from hours to 
days[44], [45].  As such, although biomarker tests are highly valuable, emergency 
room physicians cannot rely on current technologies because they are too slow to 
report the current concentration of the biomarker of interest.  Therefore, the future 
of precision medicine calls for biomarker tests that are quantitative, rapid, and 
automated.  These next-generation diagnostics will enable us to closely monitor 
and treat fast moving illnesses in the emergency room and in the field.   
 
1.6 Electrochemical aptamer sensors 
There is a new approach to biosensors which has shown great potential for 
reporting changes in protein concentration rapidly and in an automated fashion.  
Aptamers have been modified into electrochemical aptasensors by labeling the 
oligo with a redox reporter, typically methylene blue, and anchoring them to a gold 
electrode surface inside a microfluidic device via gold-thiol covalent chemistry[46].  
When the electrode is interrogated by a voltage, the redox tag may oxidize or 
reduce, and the transfer of electrons to or from the electrode gives rise to the 
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signaling current[46].  When the target protein in solution binds the aptasensor, it 
dramatically changes the conformation of the aptamer and accordingly, the electron 
transfer efficiency of the redox reporter[47].  The redox signaling current is linearly 
correlated with the protein concentration in solution[47].  Since aptamers are 
equilibrium binding affinity reagents, when the solution concentration drops, the 
aptamer releases the target and folds back into the unbound state, returning the 
current to its initial value[47].  These electrochemical aptamer binding (EAB) sensors 
are driven by miniature potentiostats that can be programmed to take current 
readings as often as every 10 seconds[47].   
Whereas previously published examples of EAB sensors were single use[47], 
our group was the first to develop the continuous EAB sensor which could monitor 
a fluctuating molecular concentration in solution over time[48].  Ferguson et al. 
developed a continuous small molecule detection system which they called 
Microfluidic Electrochemical Detector for In vivo Continuous monitoring (MEDIC) [48].  
MEDIC was able to continuously report the changing blood concentration of 
cocaine, kanamycin, and doxorubicin in live rats over several hours[48].  
Significantly, the MEDIC approach showed great potential to monitor drug dosing 
and drug metabolism in real-time. 
While EAB sensors formed the sensing component of MEDIC, the platform 
also relied on a second major innovation which permitted molecular detection to be 
done directly in blood.  The sensor electrode was protected from biofouling by a 
continuous diffusion filter (CDF) [48].  The CDF consisted of a stacked laminar flow 
where a buffer sheath separated the blood sample flow from direct contact with 
aptasensor-modified electrodes[48].  Only high-diffusivity small molecules were able 
 14 
 
to cross this barrier for sensor detection, whereas low-diffusivity biological 
interferents such as red blood cells, platelets, and proteins remained in the sample 
stream[48].  Since the chips were protected from biofouling via the CDF, 
measurements could be taken continuously over the course of hours, a clinically 
useful timescale.   
In the second half of this thesis, we describe adapting the MEDIC system 
from measuring small molecules continuously to measuring proteins, which we call 
Protein MEDIC (PMEDIC).  Specifically, we adapted MEDIC to continuously 
monitor the coagulation factor α-thrombin.  To do this, we addressed a number of 
challenges, namely, how to monitor clot formation in blood without disrupting 
microfluidic flow, how to optimize the CDF to allow for protein detection, and how to 
rapidly regenerate the aptasensors for new measurements.   
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1.7 Objectives and Outline 
Our goal is to develop new precision medicine technologies to improve the 
efficacy of medical treatment.  We utilize next generation materials engineering of 
DNA machines towards achieving this goal.  We have developed several 
interrelated technologies for controlled drug delivery as well as real-time molecular 
diagnostics.   
Chapter 2: In this section, we describe the development of pH-controlled 
DNA nanostructures which deliver an antisense DNA drug payload.  We set specific 
selection pressures to generate drug delivery vehicles which would encapsulate the 
drug payload at pH 7.5 and release at pH 5.2 within a 30 minute period.  We found 
10 sequences which would do this function with excellent pH-selectivity.  Our best 
performer released 714-fold more payload at low pH than high pH, demonstrating 
the potential of our approach for generating customized pH-controlled drug delivery 
vehicles.   
Chapter 3: In this section, we describe an extension of the selection 
technique developed in Chapter 2, used now to generate customized pH-controlled 
aptamers.  In this work, we set selection conditions to generate aptamers which 
would turn on their affinity for Streptavidin at pH 7.5 and turn it off at pH 5.2.  Thus, 
by simply changing the solution pH, we can now modulate the binding affinity of our 
aptamers for their targets.  In the future, pH control over aptamers may enable us to 
selectively activate aptamer therapeutics during endocytosis and reset aptamer-
based diagnostics with ease.   
Chapter 4: In this section, we describe the PMEDIC platform, a system for 
continuous monitoring of coagulation factor α-thrombin.  We show that by 
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combining the continuous reporting properties of electrochemical aptasensors, the 
biofouling protection of the CDF, and a pretreatment cocktail to prevent the action 
of native inhibitors in plasma, we could observe thrombin generation in situ from 
human plasma in real-time.   
Chapter 5: In this section, we describe development of a new module for the 
PMEDIC system, where we thermally regenerate the electrochemical aptasensors.  
By rapidly displacing the bound protein via thermal melting of the aptamer structure, 
we have reset the sensor to take a new measurement.  Thermal regeneration of 
PMEDIC can increase the rate of reporting up to 12-fold compared to waiting for 
sensor re-equilibration.  We achieved this effect by putting the PMEDIC chip into 
thermal contact with a programmable mini-thermoelectric heater/cooler and 
optimized the system to reset PMEDIC as rapidly as possible.   
Chapter 6: We conclude by discussing outlook and future directions for 
ongoing research.  
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Chapter 2. In vitro selection of pH-activated DNA nanostructures 
2.1 Introduction 
Cells often utilize changes in local pH to achieve molecular transport and 
processing. For example, ligands internalized by the cell are processed by the 
endosome for trafficking to specific cell compartments or further transported to the 
lysosome for degradation[26].  The pH of the late endosome (pH ~5.2) and lysosome 
(pH ~4.5) are significantly more acidic than the extracellular environment (pH 
~7.4),[26] and there has been great interest in exploiting this pH difference to 
achieve controlled delivery of drugs into the cell.[28], [49]  In particular, there is growing 
interest in pH-sensitive DNA nanostructures, because they are stable, 
programmable, and are readily integrated with other functional nucleic acids such 
as antisense DNA and siRNA.[50]  To date, most pH-sensitive DNA nanostructures 
have been constructed based on motifs that are already known to be pH-
responsive. For example, a number of investigators have incorporated the “i-motif” 
to achieve pH-triggered structure switching.[51-54] At neutral pH, the i-motif 
possesses negligible secondary structure, but in acidic conditions, non-canonical 
base-pairs form a C-quadruplex.[32]  The i-motif has been used to demonstrate rapid 
pH-controlled loading and release of a complementary DNA strand.[55,56]   More 
recently, a pH-controlled “triplex switch” has been described, which switches 
between duplex and triplex forms.[36]   
 
This chapter is adapted with permission from Fong, Faye Y.; Oh, Seung S.; 
Hawker, Craig J.; Soh H. Tom. Angewandte Chemie Int. Ed. 2016, 128, 15484-
15488. Copyright 2016 Angewandte Chemie. 
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Ricci and co-workers incorporated a triplex motif distal to the ligand binding site for 
pH-dependent allosteric control over DNA loading/release.[57]  Their strategy 
increased the variety of DNA ligands which could be delivered by placing the pH-
sensitive motif distal to the DNA binding site and the pH-sensitivity could be tuned 
by varying the CGC content of the triplex.[57]  While demonstrably powerful, the 
design of nanomachines incorporating the i-motif and triplex switch is restricted by 
pre-determined geometry and orientation requirements.[32,36,57]  Furthermore, while 
the triplex switch is more facilely tuned, the i-motif requires significant rational 
optimization to customize range of pH-sensitivity.[32, 58, 59] Moreover, strategies to 
tune the efficiency/rate of ligand release have not been investigated.   
Here we describe a selection-based approach for the de novo generation of 
pH-activated DNA nanostructures (PADNAs) with optimized pH-response 
properties. We present a new strategy where we set selection conditions to tune 
the pH-sensitivity and efficiency/rate of release.  Using our strategy, we discovered 
PADNAs that selectively release Mipomersen, an FDA-approved antisense DNA 
drug for the treatment of hypercholesterolemia,[60] with exceptional pH sensitivity—
achieving up to a ~714-fold increase in payload release at pH 5.2 compared to 7.5.
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2.2 Results and Discussion 
2.2.1 Library Design  
Our starting library comprises three domains (Scheme 2.1A). The 17-
nucleotide (nt) central domain is designed to hybridize with Mipomersen (20-nt) and 
thereby sequester it in an inactive state at pH 7.5.  The central domain is flanked by 
two randomized release domains (22- and 21-nt), which are subject to selection.  
Finally, each PADNA molecule contains forward and reverse PCR primer-binding 
sites at the distal ends of the sequence (20-nt).  All sequences are provided in the 
Supplementary Section (see 2.4.1, Table 2.S1). 
 
2.2.2 Selection of pH-activated DNA nanostructures 
We hybridized our starting PADNA library (initially comprising 100 picomoles 
or 6 x 1013 molecules) with 150 pmol of biotinylated Mipomersen, and then 
immobilized the assembly onto streptavidin (SA)-coated magnetic beads (Scheme 
2.1B). We incubated overnight in pH 7.5 buffer, and then discarded PADNAs that 
were not immobilized on the beads. Next, we challenged the assemblies with pH 
5.2 buffer and collected the PADNAs that released from the beads. We PCR 
amplified and generated single-stranded products for the next round of selection or 
for high-throughput sequencing. We performed 12 rounds of selection, increasing 
stringency in each round by decreasing the PADNA:Mipomersen ratio (for details, 
see 2.5.2.) 
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Scheme 2.1. Library design and selection of pH-responsive PADNAs.  
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At the end of each round, we performed PCR amplification of samples taken 
from the eluents, loaded them onto a polyacrylamide gel and determined the 
“release ratio”—the amount of PADNAs released at pH 5.2 in comparison to pH 7.5 
(Figure 2.1). This ratio increased over the course of selection, as seen by the 
differences in band intensities, reaching ~27 by R12. PADNAs showed minimal 
release in the presence of excess SA, confirming that they do not bind to the SA 
that was used during selection to conjugate Mipomersen to the beads.  
 
Figure 2.1. Gel images comparing the DNA eluted after 30 minutes in pH 7.5 or pH 5.2 PBSMT over 
multiple rounds of selection (lanes 2-9). Lane 1 contains the 20-bp ruler. Lane 10 shows elution of the 
R12 pool for 30 minutes in pH 7.5 buffer with 1 uM Streptavidin.  
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2.2.3 High-throughput sequencing analysis of the R12 pool 
We analyzed the R12 pool with high-throughput sequencing, obtaining more 
than 2 million sequences.  Surprisingly, the R12 pool maintained a high level of 
diversity, where the highest copy number of any single sequence did not exceed 
91.  We found that none of the 100 most abundant PADNAs contained known pH-
responsive elements such as the i-motif, poly-dA repeats,[61] or the long 
homopyrimidine/homopurine runs that are signatures of DNA triplexes.[62]  These 
results suggest that PADNAs are novel pH-sensitive structures that are 
mechanistically distinct from previously reported motifs.  
 
2.2.4 qPCR characterization of individual sequences 
We used qPCR to obtain the release ratio for the ten most abundant 
PADNAs. The release ratio of the top ten PADNAs ranged from 93–714 (see 2.4.2, 
Table 2.S2). We focused our analysis on PADNA-1 because it was the most highly 
represented in the R12 pool. PADNA-1 exhibits an excellent release ratio of 145, as 
quantified by qPCR (Figure 2.2A). We confirmed that the structure-switching 
function of PADNA-1 arises from the selected release domains by comparing our 
results with negative controls (Table 2.S2, bottom two rows).  We also measured 
release across a range of pH gradients (Figure 2.2B). First, we challenged the 
PADNA-1/Mipomersen complex with pH 9.6, and found minimal release. This 
indicates PADNA-1 responds specifically to acidic pH. Second, we observed that 
PADNA-1 shows increasing release in proportion to decreasing pH, rather than a 
sudden release of all Mipomersen at pH 5.2 (Figure 2.2B). This property is 
advantageous for continuous distribution of Mipomersen throughout the endosomal 
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maturation process, rather than delivery restricted to the late endosome where the 
pH is ~5.2. 
 
Figure 2.2. Efficiency and specificity of Mipomersen release by PADNA-1.  (A) qPCR measurements 
show PADNA-1 release from magnetic beads in response to shifting the pH from 7.5 to 5.2.  (B) 
qPCR measurements of PADNA-1 release across a range of pH from alkaline (9.6) to acidic (4.5). 
 
2.2.5 Real-time fluorescence measurement of PADNA release 
We monitored pH-dependent Mipomersen release via a real-time 
fluorescence assay. Specifically, we modified Mipomersen with 5-
carboxytetramethyl-rhodamine (TAMRA) on T4 and PADNA-1 with Black Hole 
Quencher 2 (BHQ2) on T54 (see 2.4.1, Table 2.S1). We chose TAMRA for these 
experiments because its fluorescence is known to be stable in acidic pH.[63]  When 
Mipomersen hybridizes to PADNA-1, TAMRA fluorescence is quenched. When 
Mipomersen is released by acidic pH, the fluorescence is restored (see 2.4.3, 
Scheme 2.S1).   
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First, we challenged the complex with pH 9.6 and observed no change in 
signal, confirming that PADNA-1 does not release in response to basic pH shift 
(Figure 2.3A). 
 
Figure 2.3. (A) Real-time measurement of fluorophore-labeled Mipomersen release from quencher-
labeled PADNA-1. (B) Real-time titration experiments showed that the fraction of released 
Mipomersen increases monotonically with decreasing pH. The poly-T control (gray), is a negative 
control sequence where the release domains of PADNA-1 are replaced with polyT (see 2.4.1, Table 
2.S1). As expected, the polyT control showed minimal response under identical conditions.  Data 
were normalized to the maximum value of release at pH 5.2.  Details for this calculation are 
described in Figure 2.S1. We note that the fluorescence signal measured in these experiments 
appears to decay due to photobleaching of TAMRA (see 2.4.3, Figure 2.S1). 
 
This result is consistent with our qPCR measurements (Figure 2.2B). When 
we decreased the pH to 5.2, however, we observed rapid Mipomersen release (<1 
min response time). We note that the maximum release at pH 5.2 observed in this 
assay was 50.5% of total Mipomersen. We attribute this to the TAMRA and BHQ2 
modifications, which may impede release by stabilizing the duplex.[64]  Finally, we 
cycled the pH back to 7.5 and found that Mipomersen re-loaded onto PADNA-1, 
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with free Mipomersen decreasing to ~15% of its maximum signal over the course of 
120 minutes. Re-association appears to be a slow reaction whereas release is a 
fast process. This property is advantageous for drug delivery because it ensures a 
high rate of delivery with low rates of reabsorption during endosomal uptake.  We 
further confirmed the reversibility of PADNA-1 loading and release by performing 
repeated cycling between pH 7.5 and 5.2 (see 2.4.4, Figure 2.S2).  Next, we used 
our fluorophore-quencher assay to monitor continuous stepwise pH titration 
between 7.5 and 5.2, and found that the release of Mipomersen increased 
proportionally with the gradual lowering of pH (Figure 2.3B).  These results agree 
with pH titration experiments performed via qPCR (Figure 2.2B).   
 
2.2.6 Unpacking the structure-switching mechanism of PADNA-1 
M-fold software predicted highly-ordered secondary structure for PADNA-
1,[65] where the release domains and primer regions hybridize extensively with the 
central domain (Scheme 2.2). We hypothesize that part of the structure-switching 
mechanism arises from the reversible pH-dependent stabilization of mismatch 
base-pairs, including two C-A pairs at sites (1) and (2).  Protonation of the 
adenosine N1 moiety reorganizes a C-A mismatch into a C•A+ wobble pair which 
has been reported to contribute up to -10 kcal/mol to the free energy.[66]  We predict 
that at pH 5.2, PADNA-1 adopts a low-pH conformation in which the primer and 
release domains hybridize with the central domain, thereby displacing Mipomersen.  
Interestingly, the pKa of these C-A mismatches can be estimated from Figure 2.3B 
to be ~5.5, which differs from previously reported values (~7.5) measured under 
similar conditions.[66, 67] We believe that secondary/tertiary interactions with C-A 
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mismatches may shift the pKa.  For example, it has been shown that multiple C-A 
mismatches in the same duplex can lower the pKa.[68]  In Nature, a lead-dependent 
ribozyme has been shown to contain multiple adenine bases with perturbed pKa 
values thought to be supported by tertiary interactions.[69]   
 
Scheme 2.2. Predicted secondary structure of PADNA-1. Red dots are high-free-energy mismatched 
base-pairs, orange dashes are low-free-energy mismatches, black dashes are canonical base-pairs.  
The central domain consists of 17 bases marked by filled black circles. 
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To test our model, we substituted C-T for the C-A mismatches at either or 
both sites (1) and (2) in PADNA-1, and then used qPCR to measure the resulting 
change in release ratio (Figure 2.4A).  The C-T basepair is a pH-insensitive analog 
to C-A, and would thus be expected to impede pH-triggered function.  C-T 
substitution at site (1) reduced the release ratio to 6, and substitution at both sites 
knocked out the release function completely.  Our results suggested that C•A+  
wobble pairs play a major role in stabilizing the low pH conformation of PADNA-1 
that displaces Mipomersen from the central domain. 
 
Figure 2.4. (A) MUT-1 showed decreased release at pH 5.2, yielding a reduced ΔCt value of 2.76 +/- 
0.03.  MUT-2 showed almost complete loss of function, yielding a ΔCt of 0.71 +/- 0.03. Data are also 
shown for MUT-1 release at pH 7.5 (essentially identical to data for MUT-2 and PADNA-1). Release 
from PADNA-1 at pH 5.2 is also shown, with the fit line reproduced from Figure 2.2A for comparison. 
(B) MUT-CC yielded a ΔCt of 1.71 +/- 0.07. 
 
Interestingly, we also examined mutants where we replaced the C-A 
mismatches with G-C or A-T Watson Crick base-pairs.  We found that these 
mutants released ~80% of loaded Mipomersen at pH 7.5 according to fluorescence 
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monitoring (see 2.4.5, Figure 2.S3). Since G-C/A-T basepairs would be expected to 
promote intramolecular folding of PADNA-1 at pH 7.5, these results support the 
hypothesis that stabilization of basepairs at sites (1) and (2) makes a large 
contribution to the structure-switching release mechanism.  
Since C-C mismatches are also known to form protonated wobble pairs 
(C+•C),[33] we tested whether mutants with C-C substitutions at sites (1) and (2) 
could rescue structure-switching function (Figure 2.4B). However, such mutants 
only exhibited a release ratio of 3.  Based on these observations, we believe that 
the structure-switching mechanism relies on specific tertiary interactions with 
protonated adenine residues, and this is a subject of future investigations. 
 
2.3 Conclusions 
In this work, we report a discovery-driven approach to identify pH-activated, 
structure-switching DNA nanostructures. PADNAs respond specifically to a shift 
from neutral to acidic pH, undergoing a conformational change that results in highly 
selective release of the antisense drug Mipomersen. For example, PADNA-1 
releases Mipomersen with 145-fold selectivity at pH 5.2 versus 7.5. None of the pH-
dependent structure-switching sequences we generated were related to known 
motifs, suggesting that they may operate via novel structure-switching mechanisms.  
We found strong evidence that the reversible formation of C•A+  wobble pairs 
contributes to the pH-responsive function of PADNA-1.  Although our results are 
preliminary, PADNAs demonstrate excellent potential for tightly regulated drug 
delivery.  In vitro selection offers exciting opportunities to discover new functional 
DNA motifs and we anticipate that it could be adapted to identify other sequences 
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with distinct pH response characteristics and drug release profiles.
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2.4 Supplementary section 
2.4.1 Oligos used for selection and characterization 
 
Table 2.S1. All sequences written 5' to 3'. 
 Forward 
primer FAM-AAGTGCCATCGTGCGTATCC 
Reverse 
primer Phos-TCGTCGTGTCTCCAGTCTAC 
Biotin-
Mipomersen Biotin-T20-GCCTCAGTCTGCTTCGCACC 
Lib17 AAGTGCCATCGTGCGTATCC-N22-GCGAAGCAGACTGAGGC-N21-GTAGACTGGAGACACGACGA 
PolyT 
control 
AAGTGCCATCGTGCGTATCC-T22-GCGAAGCAGACTGAGGC-T21-
GTAGACTGGAGACACGACGA 
TAMRA-
Mipomersen GCC(T-TAMRA)CAGTCTGCTTCGCACC 
BHQ2-
PADNA-1 
AAGTGCCATCGTGCGTATCCTTCACTCCTTGCTCGACAAGAAGCGAAGCAGAC(
T-BHQ2)GAGGCGTCCGATGGTCTAATTCTTCAGTAGACTGGAGACACGACGA 
BHQ2-polyT 
control 
AAGTGCCATCGTGCGTATCC-T22-GCGAAGCAGAC(T-BHQ2)GAGGC-T21-
GTAGACTGGAGACACGACGA 
GC-Q 
AAGTGCCATCGTGCGTATCCTTC(G)CTCCTTGCTCGACAAG(G)AGCGAAGCAG
AC(T-
BHQ2)GAGGCGTCCGATGGTCTAATTCTTCAGTAGACTGGAGACACGACGA 
AT-Q AAGTGCCATCGTGCGTATCCTTCACT(T)CTTGCTCGACAAGAAG(T)GAAGCAGAC(T-BHQ2)GAGGCGTCCGATGGTCTAATTCTTCAGTAGACTGGAGACACGACGA 
MUT-1  AAGTGCCATCGTGCGTATCCTTC(T)CTCCTTGCTCGACAAGAAGCGAAGCAGACTGAGGCGTCCGATGGTCTAATTCTTCAGTAGACTGGAGACACGACGA 
MUT-2 AAGTGCCATCGTGCGTATCCTTC(T)CTCCTTGCTCGACAAG(T)AGCGAAGCAGACTGAGGCGTCCGATGGTCTAATTCTTCAGTAGACTGGAGACACGACGA 
MUT-CC AAGTGCCATCGTGCGTATCCTTC(C)CTCCTTGCTCGACAAG(C)AGCGAAGCAGACTGAGGCGTCCGATGGTCTAATTCTTCAGTAGACTGGAGACACGACGA 
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2.4.2 Release ratios of PADNAs identified by HTS and negative 
controls 
Table 2.S2  
Sequence 
ID 
Copy 
number Sequences without primer sites (5' --> 3') 
Release  
ratio 
PADNA-1 91 TTCACTCCTTGCTCGACAAGAAGCGAAGCAGACTGAGGCGTCCGATGGTCTAATTCTTCA 145 
PADNA-2 86 TTCACGTTTGTTCTACAAAAGCGAAGCAGACTGAGGCGCGTGCCCTGTCGTGCACCACGG 714 
PADNA-3 83 TGAACATTGACGTGTAGTCAATGCGAAGCAGACTGAGGCGCCTCTCTAGTTTGACCTTGG 108 
PADNA-4 80 CGCTCCGCTAATATCTATGTTAGCGAAGCAGACTGAGGCGCGATGATGTCTACACTGACG 93 
PADNA-6 71 TCCGCTAACTCCGAAAGAGGTAGCGAAGCAGACTGAGGCGCGCCTCCGGCTCGTGTATCG 180 
PADNA-7 69 TTCGCAAATTTGGTTACAAATCGCGAAGCAGACTGAGGCGCGCCTTTATGTCTATTCGTT 121 
PADNA-9 65 AACTTCACGTCTTCTTGAAAACGCGAAGCAGACTGAGGCGCGTCGAATGGCCTAAACACA 231 
PADNA-13 57 TAGCTTCACGATATTTAATACCGCGAAGCAGACTGAGGCGCGTTACCTCCACAGCTTGCT 161 
PADNA-18 55 GCTTCACGTTAATTTATTACACGCGAAGCAGACTGAGGCATGCCTCCTGACGTGATCCAC 205 
PADNA-20 54 TTCATGCGGAACTTTTTCCACACGAAGCAGACTGAGGCGCGCCTTTGAGTCGATTTGTAG 201 
Lib17 - N22-GCGAAGCAGACTGAGGC-N21 <1 
PolyT - T22-GCGAAGCAGACTGAGGC-T21 1 
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2.4.3 Calculations for real time fluorescence monitoring assay 
 
Scheme 2.S1. At pH 7.5, TAMRA-labeled Mipomersen hybridizes with a BHQ2-labeled PADNA 
molecule, which quenches its fluorescence. When the pH is shifted to 5.2, Mipomersen is released 
and TAMRA fluorescence is restored. 
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Figure 2.S1. (A) Raw fluorescence data used to produce Figure 3A. Max F represents the signal 
corresponding to TAMRA-labeled Mipomersen in the absence of BHQ2-labeled PADNA-1. Max F 
decreases throughout the experiment due to photobleaching of TAMRA. (B) In order to normalize our 
results relative to TAMRA photobleaching, we calculated the % Release using Equation 1 (below).  
However, the rate of photobleaching decay for the TAMRA-Mipomersen sample differed slightly from 
the TAMRA-Mipomersen + BHQ2-PADNA-1 sample and as such, a small photobleaching artifact is 
visible. 
 
 
From the absolute fluorescence values, we calculated “% Release” as follows: 
 
 
% Release  =  Absolute fluorescence of sample / Max fluorescence  x 100%        (1) 
 
 
However, as we noted in the manuscript, the maximum % release at pH 5.2 was 
capped at 50.5%, perhaps due to the influence of TAMRA and BHQ2 modifications. 
Therefore, we calculated “Normalized % Release”, which results in the plot Figure 
3A. 
  
 
Normalized % Release  = % Release / 50.5%  x 100%             (2) 
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2.4.4 Reversible loading and release of PADNA-1 
 
Figure 2.S2. PADNA-1/Mipomersen loading and release is reversible.
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2.4.5 Real-time fluorescence monitoring of PADNA-1 mutants 
 
Figure 2.S3. Real-time measurement of fluorophore-labeled Mipomersen release from quencher-
labeled mutants of PADNA-1 where C-A mismatches at sites (1) and (2) have been replaced G-C or 
A-T Watson Crick basepairs. We found that at pH 7.5, the GC mutant (GC-Q) released 76.8% of the 
loaded Mipomersen. Similarly, the AT mutant (AT-Q) released 82.2% of Mipomersen. This is 
consistent with our hypothesis for the structure-switching mechanism because G-C or A-T basepairs 
would stabilize intramolecular folding of PADNA-1 and promote strong release of Mipomersen at pH 
7.5.  Interestingly, when the GC and AT mutants are challenged with pH 5.2, we observe further 
Mipomersen release reaching 100%. We believe this effect is likely due to the formation of additional 
favorable tertiary contacts at low pH.   
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2.5 Experimental section 
2.5.1 Reagents.  
The random ssDNA library (Lib17), Mipomersen strand, FAM-labeled 
forward primer and phosphorylated reverse primer were synthesized and purified by 
Integrated DNA Technologies (Coralville, IA). Each single-stranded DNA (ssDNA) 
library component consists of a central 60-mer region flanked by two 20-mer PCR 
primer sequences. The central region includes a 17-nt Mipomersen-binding 
sequence flanked by two randomized sequences (22- and 21-nt). GoTaq Master 
Mix and MyOne streptavidin C1 Dynabeads were purchased from Life Technologies 
(Carlsbad, CA). Unmodified PADNA clones, TAMRA-labeled Mipomersen strand, 
and BHQ2-labeled clones were synthesized and purified by Biosearch 
Technologies (San Diego, CA). SA was purchased from Roche Technologies 
(Germany). iQ SYBR Green Supermix was purchased from Bio-Rad Laboratories 
(Hercules, CA) for qPCR experiments. λ-exonuclease for single strand generation 
was purchased from New England BioLabs. 
 
2.5.2 Library Preparation and Immobilization 
Lib17 (see 2.4.1, Table 2.S1) was reconstituted as a 500 μM solution in 1X 
TE, with concentration confirmed via UV-vis measurement. We mixed 100 pmol of 
Lib17, or 6.02 x 1013 unique sequences, with 150 pmol of biotinylated Mipomersen 
and hybridized in 200 μL of pH 7.5 1X PBSMT by heating at 95 °C for 5 min, and 
then slowly cooling down to room temperature (RT) over 20 min. This mixture was 
then incubated for 20 minutes at RT with 100 μL of SA-coated magnetic beads in 
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pH 7.5 1X PBSMT. Nonspecifically bound DNA molecules were removed by 
washing library-bead assemblies with PBST buffer in which the ionic strength was 
gradually decreased (R1: no wash; R2: x2 in 1X; R3: x1 in 1X, x1 in 1/2 X, x1 in 1/4 
X; R4: do R3 wash sequence, then x1 in 1/8 X, x1 in 1/16 X, x1 in 1/32 X; R5-R12: 
same as R4). The beads were then resuspended in pH 7.5 1X PBSMT overnight. 
Afterwards, the supernatant was discarded to remove nonspecifically releasing 
sequences prior to selection. 
 
2.5.3 In vitro PADNA selection 
In R1, the library-bead assemblies were challenged with 200 μL pH 5.2 1X 
PBSMT for 30 minutes at RT. PADNA molecules that underwent acid-induced 
structure-switching were separated from Mipomersen-coated beads using a 
magnetic particle concentrator (Life Technologies). The resulting supernatant was 
PCR amplified in 100 μL PCR reactions containing 50 μL GoTaq Master Mix, 0.50 
μL 100 μM FAM-labeled forward primer and phosphorylated reverse primer, 10 μL 
PADNA molecules, and 39 μL nuclease-free water. GoTaq polymerase was 
activated prior to PCR by heating reactions to 95 °C for 15 min, followed by 25 
cycles of a three-step PCR reaction (30-s denaturation at 95 °C, 30-s annealing at 
56 °C, 30-s extension at 72 °C). 8 μL of PCR mixture was collected and resolved on 
a 10% PAGE-TBE gel to determine the optimal PCR amplification cycle number 
with minimal byproducts. Collected PADNA pools from each round were PCR 
amplified at the optimized cycle number. 
After full PCR amplification, phosphorylated double-stranded DNA (dsDNA) 
was purified using the MinElute PCR Purification Kit (Qiagen). Purified dsDNA was 
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enzymatically digested with 36 μL λ-exonuclease in 21.8 μL 10X lambda 
exonuclease buffer for 90 minutes at 37C. The resulting ssDNA product was 
purified using phenol-chloroform extraction/ethanol precipitation overnight at -80 °C. 
The resulting ssDNA pool was quantified via UV-vis at 260 nm and then prepared 
for the next round of selection. 
Over 12 rounds of selection, we systematically decreased the amount (in 
pmol) of ssDNA library to apply higher selection stringency (R1-R6: 100, R7: 10, 
R8: 2, R9-R10: 1, R11-12: 0.1). From R3 onward, we also performed negative 
selections using 1 μM SA. The negative selections were performed in 200 uL of pH 
7.5 1X PBSMT for 30 min at RT. 
 
2.5.4 High-Throughput Sequencing of Isolated PADNAs 
After 12 rounds of selection, the enriched pool was PCR amplified with 
unmodified forward and reverse primers under the reaction conditions described 
above at an optimized PCR cycle number determined by pilot PCR. These PCR 
products were then purified by the MinElute PCR Purification Kit (Qiagen) and 
sequenced with Illumina MiSeq Next Generation Sequencing at the GENEWIZ San 
Diego Laboratory using a 30% PhiX control. 
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2.5.5 PADNA Characterization via qPCR 
100 pmol of each individual PADNA ssDNA sequence was mixed with 150 
pmol of biotinylated Mipomersen and hybridized in 200 μL of pH 7.5 1X PBSMT by 
heating at 95 °C for 5 min, and then slowly cooling down to room temperature (RT) 
over 20 min. This mixture was then incubated for 20 minutes at RT with 100 μL of 
SA-coated magnetic beads in pH 7.5 1X PBSMT. Our qPCR measurement 
confirmed that 60% of our PADNAs was immobilized after the preparation step. The 
PADNA/bead assemblies were challenged with 1X PBSMT (pH 4.5 – pH 9.6) for 30 
min at RT and the eluents collected. The quantities of PADNAs released as a result 
of pH-induced structure-switching were subsequently determined by qPCR. Each 
PCR reaction contained 10 μL iQ SYBR Green Supermix, 8.8 μL PCR water, 0.1 μL 
each of 0.1 mM forward and reverse primers and 1 μL DNA template. Fluorescence 
signals were monitored using the iQ 5 multicolor qPCR Detection System (Bio-Rad) 
and a ΔCt value was determined for each pH shift. All samples were tested in 
triplicate. Release ratio was calculated from the following formula: 2ΔCt. 
 
2.5.6 PADNA Characterization via Real-Time Fluorescence 
Measurements 
We mixed 0.5 μM BHQ2-modified PADNA-1 or control sequence with 0.5 uM 
TAMRA-labeled Mipomersen and hybridized in 200 μL of pH 7.5 1X PBSMT by 
heating at 95 °C for 5 min, and then slowly cooling down to room temperature (RT) 
over 20 min. The mixtures were transferred to a black 96-well microplate (Microfluor 
2, Thermo Scientific; Waltham MA) and equilibrated for 30 minutes at RT. The pH 
was cycled between 5.2 and 7.5 using small volumes of 1 M HCl or NaOH and the 
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fluorescence emission was measured at 579 nm using a TECAN microplate reader 
(San Jose, CA) with the following settings: excitation wavelength = 525 nm, 
excitation bandwidth = 5 nm, and emission bandwidth = 5 nm. 
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Chapter 3. In vitro selection of a pH-gated structure-switching aptamer 
3.1 Introduction 
Aptamers are affinity reagents composed of nucleic acids which are 
generated by an  in vitro process known as Systematic Evolution of Ligands by 
Exponential Enrichment (SELEX)[70].  Aptamers have been found which can bind 
with high affinity and specificity to a broad range of target molecules including 
proteins[10], small molecules[71], and whole cells[72].  The ease of chemical synthesis 
and modification of aptamers as well as their high thermal stability arises from the 
material properties of being composed of nucleic acids (DNA, RNA, modified 
oligonucleotides)[70], [73].  As such, aptamers are emergent competitors to traditional 
protein-based antibodies.  Aptamers have found applications as biosensors[73] and 
as therapeutic molecules[74].  Most notably, the FDA-approved medicine, Macugen, 
is an aptamer inhibitor of vasoendothelial growth facor (VEGF) used for the 
treatment of wet age-related macular degeneration (AMD)[74]. 
Recently, there has been growing interest in developing pH-reactive 
aptamers where ‘catch-and-release’ of the ligand is controlled by changes in pH.  
Potential applications have been proposed for pH-controlled drug delivery[57], [75], 
sensors[76] , and biological separation[77].  Shastri and co-workers made use of the 
inherent pH-sensitivity of the thrombin binding aptamer (TBA) to reversibly catch 
and release its ligand[77].   
 
At the date of compiling this thesis, June 2017, this work is still in progress. The 
contents are thus presented as preliminary results. 
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However, this approach has two notable disadvantages: first, many aptamers are 
not innately pH-reactive and second, there is no method to tune the pH-switching 
behavior.  As such, several groups have designed allosteric methods to impart pH-
control by incorporating known pH-sensitive modules.  Ricci and co-workers created 
a pH-dependent cocaine-binding aptamer (CBA) by appending a pH-sensitive 
triplex motif distal to the ligand binding site[57].  The range of pH-sensitivity of their 
modified aptamer was demonstrated to be tunable by varying the %GC content of 
the triplex module[57].  Other groups have found success using the i-motif[76] and 
polyA sequence[75] to impart pH control over aptamer affinity.  Notably, strategies 
based on the i-motif are constrained by the difficulty in tuning its pH-responsive 
properties[58], [59] and applications of the polyA sequence are limited to aptamer 
sequences which are specifically G-rich in nature[75].   
Although these strategies are reasonably effective, the design of pH-
controlled aptamers is constrained by the geometry and orientation requirements of 
known pH-active motifs[32],[36]. For example, it would be extremely challenging to 
attempt to minimize the size of the pH-reactive module.  Moreover, determining the 
optimal location for insertion is not trivial, since incorporating a foreign nucleotide 
sequence could interfere with normal folding of the aptamer.  Previously, our group 
described an in vitro selection to generate novel pH-activated DNA nanostructures 
(PADNAs)[78]. We set selection conditions to tune structure-switching behavior over 
a custom pH range[78]. Here we describe a selection-based approach to generate 
pH-gated structure-switching aptamers (PGSAs) where the binding affinity is 
directly modulated by changing the pH.  As a model, we selected for PGSAs that 
selectively switch off affinity for Streptavidin at pH 5.2 and switch on affinity at pH 
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7.5 (Scheme 3.1A).  Our selection technique generated an enriched pool of PGSA 
molecules which showed a 6-fold decrease in affinity at pH 5.2 compared to 7.5. 
We obtained 82 unique sequences from the enriched pool which we are currently 
assaying for individual pH-reactivity performance.  On the basis of these results, we 
conclude that it should be feasible to adapt our selection process to generate 
aptamers with pH-controlled affinity over any desired pH range for diagnostic or 
therapeutic applications.  
 
3.2 Results and Discussion 
3.2.1 Library design 
Our starting library (Lib_Min) comprises three domains (Scheme 3.1B). The 
29-nucleotide (nt) central domain is a well known Streptavidin binding aptamer 
(SBA29) with a Kd of ~100 nM as previously reported by several groups[79-82].  
SBA29 is thought to form a stem-bulge-loop structure[19] with moderate affinity for 
the biotin binding sites of Streptavidin[79],. The central domain is appended to a 16-
nt randomized release domain which is subject to the forces of selection.  In this 
arrangement, the release domain may fold with the central domain to disrupt the 
functional structure of SBA29 and turn off affinity for Streptavidin at low pH.  Finally, 
each PGSA molecule contains forward and reverse PCR primer-binding sites at the 
distal ends of the sequence (20-nt).   
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3.2.2 Selection of pH-gated structure-switching aptamers 
We selected PGSA molecules capable of pH-controlled structure-switching 
by incubating the library with Streptavidin (SA)-coated magnetic beads at pH 7.5, 
and later isolating the molecules that selectively release from the beads when 
challenged with pH 5.2 (Scheme 3.1C, see 3.4 for details).  Specifically, we applied 
10 pmols of our starting library to SA-coated magnetic beads, allowing the library to 
become immobilized by binding via the SBA29 central domain.  We equilibrated 
overnight in pH 7.5 buffer, and then discarded molecules which were not 
immobilized on the beads.  Next, we challenged the assemblies with pH 5.2 buffer 
and collected PGSAs which released from the beads.  We PCR amplified and 
generated single-stranded products for the next round of selection or for bacterial 
cloning and sequencing.  We performed 6 rounds of selection, systematically 
increasing selection stringency by applying additional SA-coated magnetic beads to 
the sample during the pH 5.2 elution steps.  This technique increased the number 
of available SA binding sites to make PGSA re-binding more favorable, thus 
increasing the stringency of selection for structure-switching release. 
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Scheme 3.1. Design and selection of Streptavidin PGSAs. (A) Our PGSA was designed to switch 
structure in response to decreased pH, disrupt normal folding of the aptamer and switch off its affinity 
for Streptavidin. This liberates Streptavidin and restores its biological functions. (B) We in vitro 
selected our PGSA from a library of DNA molecules comprised of a 29-nt binding domain (black) 
appended to  a randomized 16-nt release domain (blue), and flanked by two 20-nt PCR primer sites 
(grey).  The binding domain consists of the Streptavidin binding aptamer SBA29 previously described 
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by Bing and co-workers, which is known to have bind Streptavidin with a Kd ~100 nM[79].   (C) 
Overview of the selection process.  First, we incubated 10 pmol of PGSA library with SA-coated 
magnetic beads in pH 7.5 selection buffer and allowed the reaction to reach binding equilibrium 
overnight. Next, we challenged the PGSA-bead assemblies with pH 5.2 selection buffer and eluted 
PGSA molecules capable of structure-switching.  The eluent was PCR-amplified and purified single-
stranded DNAs were generated. This enriched pool was then prepared for the next round of 
selection.  Over the course of the selection, we tuned selection stringency by applying additional SA-
coated magnetic beads to the sample before the pH 5.2 buffer challenge.  Excess SA binding sites 
makes re-binding more favorable, and thus, only the most efficient structure-switchers will release 
from the beads and be collected for further enrichment.  At the end of the selection, the enriched pool 
was cloned via bacteria and sequenced. 
 
3.2.3 Enriched PGSA pool shows pH-controlled structure-switching 
At the end of each round, we PCR-amplified samples taken from the eluents 
and ran gel electrophoresis to determine the “release ratio” – the amount of PGSAs 
released at pH 5.2 compared to pH 7.5 (Figure 3.1).  This ratio increased over the 
course of the selection, as seen by the differences in band intensities, reaching ~6-
fold by R6.  As such, the enriched pool exhibited clear structure-switching 
functionality in response to pH change.  We also examined the amount of DNA 
eluted in the absence of excess SA stringency challenge and found that ~9-fold 
more DNA is eluted at pH 7.5, demonstrating that this is an effective method to 
increase selection stringency for structure-switching release. 
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Figure 3.1. Gel images comparing the DNA eluted after 30 minutes in pH 7.4 or pH 5.2 selection 
buffer over multiple rounds of selection (lanes 2-11 and 13-14). Lane 1 contains the 20-bp molecular 
ruler. Lane 12 shows elution of the R6 pool for 30 minutes in pH 7.5 buffer without excess SA 
stringency challenge.  
 
 
3.2.4 Identification of individual PGSA sequences 
We analyzed the R6 pool with bacterial cloning and sequencing, obtaining 
82 unique sequences (Table 3.1). In our sequence alignment, we found that our 
PGSAs did not contain known pH-responsive modules such as the i-motif[58], the 
triplex switch[57], or poly-dA repeats[61]. These results suggest that PGSAs inhibit 
SBA29 binding affinity through novel pH-controlled mechanisms.   
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Table 3.1. PGSAs identified by Sanger sequencing 
Sequence 
ID 
Sequences without primer 
sites (5' --> 3') 
Copy 
number 
PGSA-1 GGAGCGTGCGAAACG 2 
PGSA-2 ATTACGCTGCCGACG 1 
PGSA-3 GGCTTGAGCATAACG 1 
PGSA-5 GGAGCCCTGACGGAG 2 
PGSA-6 TGTTACGCCCGAACG 1 
PGSA-7 GGATATGCTTTGCCG 1 
PGSA-8 GATACTCTGAAGGGG 1 
PGSA-9 GGGCCCAACGCGTTC 1 
PGSA-10 GGTGTAAATACGACG 1 
PGSA-11 GGAAATCAATAGGGA 1 
PGSA-12 AATCTAAAGTAGGGT 1 
PGSA-13 GGGCTACGCCACTAG 1 
PGSA-14 GGATGAGATGCGTAG 1 
PGSA-15 GGAAATTAACTAGCG 1 
PGSA-16 AGGATCGCCGTGGAG 1 
PGSA-17 GGTGAGCGATAGTTG 1 
PGSA-18 CGATTCGCACGACCGT 3 
PGSA-19 GAGAGCATCAAGGAGG 1 
PGSA-20 TTGATCCGTGAGGGGT 1 
PGSA-21 GGAGACTCTCGGAGTA 1 
PGSA-22 TGTATCGCCTTTACGT 1 
PGSA-23 GAATCGCGCCTCTAGT 1 
PGSA-24 GGACTCATAAACGCGT 1 
PGSA-25 GAGTATTGCACGACGN 1 
PGSA-27 GTTATTACGTGTACGT 1 
PGSA-28 GTGCTACGCCTCTTGT 1 
PGSA-29 AAGATCGTACTGTTGT 2 
PGSA-30 GGAAAAGGCCGCTCGT 1 
PGSA-32 GTGCAGATGGGTCAGT 1 
PGSA-33 GAACGCCCCAAGTGGT 1 
PGSA-34 CGGAGCCNCCCGGAAG 1 
PGSA-35 GGACTAGGAGTAACGT 1 
PGSA-36 AGGGGACGCGCCCCGT 1 
PGSA-37 GGGAGCGCTGGGTCGG 1 
PGSA-38 TGTATACGAGTGGCGT 1 
PGSA-39 GGACTCCCAGAGTTGG 1 
PGSA-40 GGATAGAGGCGATCGG 1 
PGSA-41 GGGGAGCCTTAACCGT 2 
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PGSA-42 GCCAGATATCCGTGGT 1 
PGSA-43 GGGTACTTTCGTACGG 1 
PGSA-44 GGAATTAGTGCGTTGT 1 
PGSA-45 TTATCGCTACTGTTGT 2 
PGSA-46 GGAGATCTTAGGGTGT 1 
PGSA-48 TGATCGCTTGCGTAGT 1 
PGSA-50 TTACGCCGGCTGTGGT 1 
PGSA-51 GGATGCCTCACTGAGT 1 
PGSA-52 GGTACGCAGGCCGTGT 1 
PGSA-53 ACAAACGCATAGTCGA 1 
PGSA-54 GGTTCCCGCCTNACGG 1 
PGSA-56 GGATAGAGTACAGAGT 2 
PGSA-58 GTTATCGCCCGTTCGG 1 
PGSA-59 GTACGCCGCAGGTTGT 1 
PGSA-60 GTAGGATATCGCAAGT 1 
PGSA-62 AGGGTACGCCCAAAGT 1 
PGSA-63 GGTTCGGGCCCGAAGT 1 
PGSA-64 GGATTGTGATAGCCGT 1 
PGSA-65 CAGCACGTAATCTAGT 1 
PGSA-66 AGGAACGCTAAGACGT 1 
PGSA-67 GATACTATAAACAAGT 1 
PGSA-68 GTATTACGACGTCGGT 1 
PGSA-69 GATCGCCGCATTCCGT 1 
PGSA-70 GTATCGCCGCCTGAGT 2 
PGSA-71 GGAGCGAACAGGGAGT 1 
PGSA-72 GGATCGGCAGCGTTGG 1 
PGSA-74 GAGTACGGGAAGGGGT 1 
PGSA-75 GATGCCGCGTTGTTGT 1 
PGSA-76 GAGTAAGCATCGTCTT 1 
PGSA-77 GGACCGGTAGCGTCGA 1 
PGSA-78 GATGCACGATAGTGGT 1 
PGSA-79 GGGTGCATTATGTAGT 1 
PGSA-80 GGACATCCTTAGACGG 1 
PGSA-81 GGAGGCCTCGCGTAGT 1 
PGSA-82 GTTATATCGCATTCGT 1 
PGSA-83 GATCGCCATTTGGAGG 1 
PGSA-84 GACTACGGCCGTCCGG 1 
PGSA-86 TATACGCCGGACTCGG 1 
PGSA-88 GGAAAGAGGGTCGCGT 1 
PGSA-89 GAGCAGCCAATCTAGT 1 
PGSA-90 GGGGAGCCCGCGACGG 1 
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PGSA-92 CGGAGCCGCCCCCCGT 1 
PGSA-93 GGGTTAGCCGCGTAGT 1 
PGSA-94 CGTAATACGCCGACGT 1 
 
3.2.5 Structure-function relationship of PGSAs 
M-fold software was used to predict the secondary structure of the 8 PGSAs 
with copy number >1 when sequenced65].  In particular, PGSA-45 is of interest 
because the predicted secondary structure in solution does not form the expected 
stem-bulge-loop of SBA29 (Figure 3.2A). Instead, the release domain is predicted 
to partially fold with the binding domain forming a stem loop (Figure 3.2B).  The 
loop is relatively large, comprising 16 basepairs, which offers a significant energetic 
penalty at pH 7.5.  However, we hypothesize that at pH 5.2 several low-pH 
stabilized wobble pairs (C•A+, C+•C, A+•G)[33],[61],[66] may facilitate the formation of a 
stable low-pH conformation that outcompetes the functional SBA29 structure and 
collapses binding affinity for Streptavidin (Figure 3.2C).  These simulations suggest 
that PGSA-45 may be induced to form functional SBA29 in the presence of 
Streptavidin at pH 7.5 (Figure 3.2A).  As the pH decreases, it may pass through 
intermediate states (Figure 3.2B) and then achieve a stable conformation at pH 5.2 
which releases Streptavidin (Figure 3.2C).  As this work is still in progress, we 
require additional data to comment further on the mechanism.  We plan to examine 
variants of PGSA-45 where the putative low-pH-stabilized basepairs have been 
replaced with pH-insensitive analogs in order to establish which sites are most 
critical for pH-gated structure-switching. 
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Figure 3.2. Predicted secondary structures of PGSA-45. (A) Structure predicted when constrained to 
form stem-bulge-loop of functional SBA29. (B) The lowest energy competing structure formed at pH 
7.5, which may be an intermediate between (A) and (C).  (C) Hypothetical low-pH-stabilized structure 
at pH 5.2. Acid-stabilized wobble pairs (red dots) at sites (1), (2), and (3) may promote formation of a 
strongly stabilized duplex at pH 5.2, thus outcompeting the functional binding form of SBA29.  Low 
energy mismatches (orange dashes) and high energy mismatches (blue dots) are also noted. 
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3.3 Conclusions 
In this work, we have demonstrated that PGSA SELEX is an efficient and 
highly tunable platform for the generation of pH-gated structure-switching aptamers.  
Using this method, we performed a selection against Streptavidin protein and 
selected for high affinity binding at pH 7.5, which is turned off by a structure change 
induced by decreasing the pH to 5.2.  Within six rounds of selection, we obtained 
an enriched pool which showed high affinity binding at pH 7.5, and a 6-fold 
decrease in affinity at pH 5.2.  We obtained 82 unique sequences from bacterial 
cloning and sequencing which we are currently testing via qPCR assay for 
individual pH-reactive structure-switching performance.  We also plan to measure 
mutants of these sequences in order to definitively describe the pH-induced 
mechanism of structure-switching. 
We designed this selection to demonstrate that a very small (16-nt) 
randomized region can be effectively selected to exert pH-control over aptamer 
affinity.  Minimizing the size of the DNA construct is useful because it enables 
potential applications such as endocytic drug delivery, where charge and size 
exclusion are important factors[26].  We believe that future experiments should entail 
selections with varying sizes of randomized regions to balance size with 
performance. 
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3.4 Experimental section 
3.4.1 Reagents 
The random ssDNA library (Lib_Min), FAM-labeled forward primer and 
phospohrylated reverse primer were syntheiszed and purified by Integrated DNA 
Technologies (Coralville, IA).  Each single-stranded DNA (ssDNA) library consists 
of a central 45-mer region flanked by two 20-mer PCR primer sequences.  The 
central region includes a 29-nt Streptavidin-binding sequenced adjacent to a 
randomized sequence (16-nt).  GoTaq Master Mix and MyOne Streptavidin C1 
Dynabeads were purchased from Life Technologies (Carlsbad, CA).  Minelute PCR 
clean-up kit from Qiagen was used to recover purified amplicons after PCR 
amplification (Hilden, Germany).  λ-exonuclease for single strand generation was 
purchased from New England Biolabs (Ipswich, MA).   All other reagents were 
purchased from Fisher Scientific.  The selection buffer (SB) is prepared from 20 
mM Tris-HCl, 100 mM NaCl, 2 mM MgCl2, 5 mM KCl, 1 mM CaCl2, and then the pH 
is adjusted to either pH 7.5 or pH 5.2 via 1M HCl. 
 
3.4.2 Library Preparation and Immobilization 
Lib_Min was reconstituted as a 500 uM solution in 1X TE, and the 
concentration was confirmed via UV-Vis measurement.  We measured out 10 pmol, 
or 6.02 x 1012 sequences into 100 ul SB, heated at 95°C for 10 min, snap cooled 
the solution to 4°C for 10 min, and then equilibrated to RT for 10 min to promote 
intramolecular DNA folding. We applied this heat-treated solution to 8 ul of MyOne 
C1 SA-coated magnetic beads plus 92 ul of SB for a total sample volume of 200 ul.  
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This mixture was incubated for 1 h at RT with rotation.  Nonspecifically bound DNA 
molecules were removed by washing library-bead assembles with SB x3.   
 
3.4.3 In vitro PGSA Selection 
In R1, the library-bead assemblies were challenged with 200 ul pH 5.2 SB for 
30 m at RT.  PGSA molecules that switched structure and released from the beads 
at low pH were separated from SA-coated beads using a magnetic particle 
concentrator (Life Technologies).  The resulting supernatant was PCR amplified in 
100 uL PCR reactions containing 50 uL GoTaq Master Mix, 0.50 uL 100 uM FAM-
labeled forward primer and phosphorylated reverse primer, 10 uL PGSA molecules, 
and 39 uL nuclease-free water. GoTaq polymerase was activate prior to PCR by 
heating reactions to 95°C for 15 min, followed by 25 cycles of a three-step PCR 
reaction (30-s denaturation at 95°C, 30-s annealing at 56°C, 30-s extension at 
72°C). 8 uL of PCR mixture was collected resolved on a 10% PAGE-TBE gel to 
determine the optimal PCR amplification cycle number with minimal high molecular 
weight byproducts. Collected PGSA pools from each round were PCR amplified at 
the optimized cycle number. 
After full PCR amplification of the supernatant, phosphorylated double-
stranded DNA (dsDNA) was purified with the MinElute PCR Purification Kit 
(Qiagen).  Purified dsDNA was enzymatically digested with 36 uL λ-exonuclease in 
21.8 ul 10X exonuclease buffer for 90 m at 37C.  The resulting ssDNA product was 
purified via phenol-chloroform extraction and ethanol precipitation overnight at -
80°C.  The concentration of the purified ssDNA product was quantified via UV-Vis 
at 260 nm and then prepared for the next round of selection.  
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Over 6 rounds of selection, we systematically increased the stringency of 
selection by applying additional SA-coated magnetic beads (in ul) during the pH 5.2 
challenge step (R3: 100, R4: 150, R5: 180, R6: 400).  
 
3.4.4 Bacterial cloning and sequencing 
After 6 rounds of selection, the enriched pool was PCR amplified with 
unmodified forward and reverse primers under the PCR reaction conditions 
described above and purified with the MinElute PCR Purification Kit (Qiagen).  We 
mixed 256 pg of the purified amplicons with 1 uL of TOPO vector, 1 ul of salt 
solution, and 3 ul nuclease-free water from the TOPO TA Cloning kit (Life 
Technologies) and incubated at RT for 5 m.  We transferred this mixture to 1 vial of 
One Shot Mach1-T1R competent E coli and heat shocked for 30 s in a 42°C heat 
block, and then immediately put the reaction on ice for 2 m.  We added 250 ul SOC 
medium and shook at 37°C for 1 hour at 225 rpm.  We spread this solution onto 
pre-warmed agar plates containing 50 ug/ml kanamycin and allowed the colonies to 
grow overnight.  The next day, we picked 94 colonies and transferred them to a 
gridded agar plate and sent it to the GENEWIZ San Diego Laboratory for Sanger 
sequencing. 
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3.5. A pragmatic guide on how to tune up a selection 
In this section, we would like to describe the crucial preparation we 
performed to bring up a novel selection platform, an aspect which is not typically 
described in published articles.  We hope to communicate practical information that 
will help new researchers develop selection schemes that are more likely to work. 
 
3.5.1 Preparing a target protein 
In bead-based selection schemes, the first bottleneck encountered will be 
the variable yield when conjugating target proteins to magnetic beads.  Simply 
speaking, if you cannot attach your protein of interest to magnetic beads, you have 
to try alternative selection schemes (nitrocellulose membrane binding[83], capillary 
electrophoresis[84], or particle display SELEX[85] are possibilities).  
The most common method of conjugating proteins to beads is via EDC/NHS 
reaction.  The EDC/NHS method activates primary amines in the protein to react 
with carboxylic acid groups on the bead surface, forming covalent amide bonds[86].  
In general, we have found that <15% of input protein will be successfully attached 
to the beads.  We believe this happens when few primary amines on the protein are 
available for conjugation, perhaps due to shielding by the protein’s tertiary structure 
or steric hindrance from post-translational glycosylation.   
Originally, our first choices for target proteins were IgE and VEGF because 
the aptamers for these proteins, D17.4[87] and SL2-B[88], are well-characterized, 
length-minimized, high affinity binders.  However, both IgE and VEGF showed 
negligible conjugation to magnetic beads.  The result was consistent with previous 
literature, where selections for IgE and VEGF aptamers used a capillary 
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electrophoresis or filter-binding setup and thus, did not require bead conjugation.  
Eventually, we chose Streptavidin to be our model system because Streptavidin-
coated magnetic beads were available off-the-shelf (Thermo Fisher Scientific).  To 
expand our PGSA selection technique to other proteins, we recommend adapting 
the process to non-bead-based selection methods. 
 
3.5.2 Designing a selection library 
A typical selection library is 100 bp or fewer in length and these are readily 
synthesized by commercial suppliers.  Although currently some companies, such as 
Integrated DNA Technologies, offer synthesis of so-called ‘Ultramers’ which can be 
up to 200 bp in length, the pros and cons of selection with such a long library are 
not well understood.   
We wanted to design a selection library that would minimize the size of our 
construct but still have sufficient diversity to evolve our desired function. As such, 
we limited ourselves to designs with a 100 bp maximum length.  We considered 
three different strategies for library design (Scheme 3.2). Design 1 incorporated the 
full SBA29 sequence flanked by two randomized regions (15-nt and 16-nt) (Scheme 
3.2A).  Design 2 contained SBA29 adjacent to one randomized region (16-nt) 
(Scheme 3.2B). Design 3 contained an SBA29 truncate flanked by two randomized 
regions (18-nt and 19-nt) (Scheme 3.2C).  In Design 3, the first and last three bases 
of the aptamer are truncated in order to re-select the properties of the stem in 
SBA29.  Design 3 was informed by a Hg2+-controlled Streptavidin binding aptamer 
reported by Mei and co-workers, where one or more basepairs  in the stem of 
SBA29 were replaced with T•T mismatches[89].  In the absence of Hg2+, the 
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sequence would unfold, but when Hg2+ intercalated with T•T mismatches, the stem 
was stabilized and SBA29 binding affinity is restored[89].  Thus in Design 3, we 
reasoned that we could truncate SBA29 and select for a stem with pH-responsive 
basepairs.  
 
 
Scheme 3.2. The library designs considered for PGSA SELEX. (A) Design 1 contains the full SBA29 
sequence and two randomized release domains to maximize sequence diversity. (B) Design 2 also 
contains the SBA29 binding domain, but has only one adjacent randomized domain, selecting for a 
size minimized construct. (C) Design 3 incorporates a SBA29 truncate, in order to re-select the 
SBA29 stem for pH-reactivity. 
 
Chronologically, we attempted Design 3 first.  However, after six rounds, 
there was no visible enrichment so we stopped (Figure 3.3).  We do not definitively 
know why this design was unsuccessful, but we hypothesize that truncating SBA29 
led to re-selection for binding affinity, rather than pH-sensitivity.  We could confirm 
this hypothesis by sequencing the pool to see if the library re-selected for the 
original stem of SBA29. 
 
 59 
 
 
Figure 3.3.  Gel image showing comparing the DNA eluted after 30 minutes in pH 7.5 or pH 5.2 SB 
after 6 rounds of selection using Library Design 3 (lanes 2-4).  The amount of DNA eluted at pH 5.2 
was virtually the same as at pH 7.5, suggesting that there was no enrichment for pH-reactive 
structure-switchers.  While the bands corresponding to pH 5.2 eluents appear to have some 
additional mass compared to pH 7.5, it is a distinct high molecular weight byproduct of PCR 
amplification.  Lane 1 contains the 20-bp ruler. 
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Next, we pursued Design 2 because we wanted to investigate whether a very 
small randomized region could be selected for pH-responsivity.  Design 2 was a 
success and yielded an enriched pool as described earlier in this chapter (Design 2 
is named Lib_Min, see 3.2.1).  In the future, we would like to try Design 1 to see if 
randomized regions flanking both sides of SBA29 may yield even more effective 
pH-control over structure-switching. 
We would also like to comment on the importance of designing unique 
primers for each selection library.  Primer binding sequences (typically 20-nt) are 
built into all selection libraries for the purpose of specific PCR amplification of the 
oligo of interest.  Re-using primer sequences can lead to cross-contamination, 
where other people’s libraries become amplified in your pool and convolute your 
selection.  There are excellent guides online for designing primers[90].  A shortcut is 
to use primers previously published in the literature, but if you do so, your 
laboratory group must maintain a master list so that individual researchers do not 
accidentally use the same set.  
 
3.5.3 Measuring the loading efficiency of the library 
PGSA selection is a sub-type of “Falling-off SELEX” [39],[91], where the library 
starts out “loaded” onto a bead or other surface, and when challenged with a 
stimulus, some sequences switch structure and release into the eluent, which is 
amplified and used for subsequent rounds of selection.  It is important to load a 
sufficient amount of library molecules onto the beads to achieve satisfactory 
coverage of library diversity.  For example, if you have 1012 unique sequences in 
your library, it would be ideal to have at least 1012 library molecules load onto the 
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beads for 1X coverage.  If you have 1012 unique sequences, but you can load 1013 
library molecules, you will achieve 10X coverage. 
In our system, we incorporated the SBA29 sequence (Kd ~100 nM) into the 
PGSA library to give it inherent loading affinity for Streptavidin-coated magnetic 
beads.  However, we were concerned that the PGSA library could have significantly 
reduced loading efficiency compared to SBA29 because it is known that 
unminimized aptamers have poor affinity for their targets.  As such, we performed 
an experiment to measure the loading efficiency given our chosen selection 
conditions (Figure 3.4).  We combined 10 pmol of PGSA library with 8 ul SA-coated 
beads (~100 pmol of SA) and equilibrated this loading reaction (Rxn) for 1 hour.  
Afterwards, we recovered the beads via MPC, washed 3 times with selection buffer, 
and then ran the sample on a polyacrylamide gel with a standard curve. We 
determined that that the amount of DNA loaded onto SA-coated beads, or loading 
fraction (LF), was ~12% of the input, or 1.2 pmols.  Since the PGSA library has 16 
randomized bases or 416 unique sequences, 1.2 pmol provides 168X coverage.  
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Figure 3.4. Measuring the loading efficiency of the starting PGSA library (Design 2, Scheme 3.2B). 
Lane 2 shows the amount of DNA bound to 8 ul of SA-coated magnetic beads, or loading fraction 
(LF).  We compared this to a standard curve (lanes 3-6) derived from serial dilution of the loading 
reaction (Rxn).  Comparing the density of the bands in lanes 2 and 4, we calculated that the loading 
efficiency was ~12%, or 1.2 pmol of PGSA library loaded onto the beads, offering suitable coverage 
of the library diversity. 
 
We note that it is also important to confirm that the library is loading onto SA-
coated beads via specific binding between SBA29 and the biotin site of 
Streptavidin.  This is because in the elution step of PGSA selection, it is desirable 
to only collect sequences which have released by disrupting specific binding of 
SBA29 to the biotin site of Streptavidin.  In the future, we plan to confirm the 
specificity of PGSA library loading by performing a competition assay with biotin. 
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3.5.4 Round-to-round monitoring via comparative elution assay 
You should always have a method to assess at each round if your selection 
is progressing and whether enrichment is occuring at a suitably fast rate. To do this, 
we developed a “comparative elution assay”, where we take samples from 4 
eluents during the selection, run these on a PAGE gel and compare the band 
densities of the eluted DNA (Figure 3.5).  The four eluents represent: the first 30 m 
elution at pH 7.5, the second 30 m elution at pH 7.5 after stringency challenge has 
been applied, the first 30 m elution in pH 5.2, and the second 30 m elution in pH 5.2 
as a replicate (lanes 9-12, Figure 3.5). 
 When we performed this comparative elution assay using the loaded beads 
from Figure 3.3, the results were close to ideal expected behavior.  The amount of 
DNA eluted at pH 7.5 (lane 2) was about the same as the amounts eluted at pH 5.2 
(lanes 3, 4).  This result is expected in R1 where there has not yet been significant 
enrichment for structure-switchers.  As you perform further rounds, and if the pool is 
enriching, you would expect the pH 5.2 elution bands (3, 4) to increase in density 
when compared to the pH 7.5 elution band (2) (see Figure 3.1, section 3.2.3), i.e. 
you would like to see your “release ratio” increase.  We discuss an example of an 
undesirable result later in section 3.6.6 (Figure 3.7). 
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Figure 3.5. Comparative elution assay for R1 calibration experiment.  Lane 9 shows the DNA eluted 
in pH 7.5 SB for 30 m. Lane 10 shows the DNA eluted in pH 7.5 SB after stringency challenge has 
been applied. The DNA eluted at pH 5.2 is shown in lanes 11 and 12. Lanes 2-7 represent a standard 
curve created by serial dilution of the initial loading reaction Rxn.  
 
The second function of a comparative elution assay is to measure the 
enrichment rate of the selection pool.  In general, it is desirable to collect 1% or less 
of the input DNA for every round of selection, or in other words, to reduce the 
diversity of sequences in your pool by 102. That way, if you start from a pool of 
~1011 diversity as we did, you can estimate that the pool will converge in 
approximately ~6 rounds.  We compared the elutions taken at pH 5.2 (lanes 11 and 
12, Figure 3.5) with a standard curve (lanes 2-8, Figure 3.5) and found that ~0.8%, 
or 0.008 of the bead-bound library was eluted. Therefore, we estimated that 
enrichment is occuring at ~102-fold per round, as desired. 
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We note that we performed comprehensive comparative elution assays for 
every round of PGSA SELEX to monitor selection progress.  However in Figure 3.1, 
for clarity’s sake, we cropped the assay to just show increasing “release ratio”, 
demonstrating pool enrichment. 
 
3.5.5 Developing a stringency challenge method 
In order to maintain a fast enrichment rate, it is necessary to have a 
straightforward and tunable strategy for increasing the stringency of selection.  In 
the case of falling-off SELEX, the stringency strategy must increase favorability of 
the pool re-loading onto beads.  As such, only the best structure-switchers can 
overcome the increased energy barrier for release into the collected eluent.  For 
PGSA SELEX, we developed a stringency strategy where we added excess SA-
coated beads to the sample after initial library loading had been performed.  The 
increased number of SA binding sites favored re-loading of the library onto beads, 
raising the energy barrier for structure-switching release.   
To measure the effect of our stringency challenge at each round, we 
compared the bands corresponding to the amount of DNA eluted at pH 7.5 before 
and after the stringency challenge (lane 9 vs 10) to determine the “stringency ratio” 
(Figure 3.5).  In this example, ~10-fold less DNA eluted into solution when the 
stringency challenge was applied, indicating that our strategy is indeed creating a 
higher energy barrier for structure-switching release (1:10 stringency ratio) (Figure 
3.5).   As the pool becomes enriched over the course of selection, the average 
release efficiency also increases.  Therefore, the stringency challenge must 
continuously be increased to pick out the best structure-switchers.  The stringency 
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ratio measured in the previous round helps us to decide how much to increase the 
strength of the challenge in the next round. 
We would like to make an important technical comment, which is that as you 
increase the amount of beads applied for stringency, it is important to wash your 
sample several times in the elution buffer of the next step and check the pH before 
submitting to a full 30 m elution.  The reason for this is that a large bead pellet 
collected on the MPC is still hydrated by a significant amount of buffer from the 
previous elution, which can deleteriously alter the pH of the next elution.  For 
example, we found that when transitioning from a pH 7.5 to 5.2 elution step, while 
using 400 ul of SA-coated beads, the nominally pH 5.2 elution was actually found to 
have a pH of ~6.6 (Table 3.2).  This is undesirable because it means that you are 
selecting for structure-switchers activated by pH 6.6, not your target pH of 5.2.  
 
Table 3.2. Buffering effect of increasing stringency challenge beads 
 
Stringency challenge beads (ul) 
 
100 150 180 400 
Nominal pH 5.2 5.2 5.2 5.2 
Measured pH 5.2 5.5 6.0 6.6 
Measured pH (3x wash) 5.2 5.2 5.2 5.5 
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There are other methods to apply a stringency challenge. Instead of 
increasing the amount of SA-coated beads, you can decrease the amount of input 
DNA, such that the ratio of Streptavidin:DNA is still increased.  Decreasing the 
temperature of the system during the elution or lowering the ionic strength of the 
buffer will also increase stringency.  These alternative techniques may be used to 
continue increasing stringency even after the practical handling volume of SA-
coated beads (~1000 ul) has been reached. 
 
3.5.6 Choosing a suitable selection buffer 
Many different “biological” buffers (PBS, MES, Tris, other “Good’s Buffers”) 
have been used for aptamer selection.  The most important consideration for PGSA 
SELEX was to choose a selection buffer which supported the correct folding of 
SBA29, and therefore, high loading efficiency of the PGSA library onto beads. In 
previous papers describing selection for Streptavidin aptamers, PBS + Tw-20 pH 
7.4 was used, so we chose to try this buffer first[79-82].  We performed a comparative 
elution assay (using the same selection conditions as 3.6.3) and oddly, found that 
the amount of DNA steadily decreased in chronological order of elution, regardless 
of the buffer pH (Figure 3.6).  This trend stands in contrast to the expected behavior 
discussed in Figure 3.5, where there should be uniform bands for both pH 7.5 and 
5.2 elutions in R1.  Based on this evidence, we believe that SBA29 actually has 
relatively poor affinity for Streptavidin in PBS + Tw-20 (we note that Bing and co-
workers never reported the Kd of the enriched pool in PBS + Tw-20, only the Kd of 
the minimized aptamer in Tris buffer[79]).  We hypothesized that each “elution” acted 
as a wash step; that is, the weakly associated library molecules were washed off 
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the beads with each “elution”.  We concluded that PBS + Tw-20 was not a good 
buffer for PGSA SELEX. 
We revisited the literature and found that while PBS + Tw-20 was used for 
aptamer selection, 20 mM Tris buffer was used universally among several follow-up 
papers for binding characterization of SBA29[79-82].  We surmised that proper folding 
of SBA29 is dependent on 20 mM Tris-HCl buffer, so that is what we used for all 
subsequent work (see Figs.3.1, 3.3-3.5, Experimental section for full recipe).  We 
note that this result illustrates an important aspect of analyzing previous literature 
when designing your own experiments.  Be suspicious of differences between 
selection conditions and characterization conditions.  Pay attention to what 
protocols are preferred by follow-up papers.  It is the unexplained changes which 
demand close inspection. 
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Fig 3.6. Comparative elution assay of Library Design 2 conducted in PBS + Tw-20 under standard 
selection conditions. The amount of DNA released into the eluent decreases in chronological order, 
and with no relation to buffer pH. The trend suggests that the library has poor affinity in PBS + Tw-20, 
and that each “elution” is washing off non-specific binding. 
 
3.5.7 Final remarks on tuning up a selection 
Performing a selection is extremely costly, both in time and money.  A single 
round of selection requires 2-3 days on average to complete, and depending on the 
initial diversity of your library, may require ~8 rounds to see evidence of enrichment.  
The largest recurring monetary cost is PCR mix, where every round requires 4 mLs 
of reagent, and the cost for 25 mLs is ~$500.  As such, it may take up to a month 
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and $1000+ to determine that your selection is not working.  Multiple iterations of 
such selections can lead to years of opportunity cost for the researcher. 
In our experience, success comes if more time is spent on design and 
preparation than the act of carrying out a selection.  First and foremost, determine 
the simplest scheme to create selection pressure in your system to evolve your 
desired function.  Second, design your selection libraries based on a reasonable 
hypothesis for how changes in DNA folding can carry out your desired function.  
Third, develop a method to estimate the rate of pool convergence (loss of diversity).  
Knowing the rate of convergence allows you to estimate when you can expect signs 
of enrichment for a successful effort and conversely, when to go back to the 
drawing board.  When it comes to SELEX, it is great to succeed, but good to fail 
quickly. 
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Chapter 4. Continuous in situ generation and detection of α-thrombin 
protein via a real-time electrochemical aptasensor (PMEDIC) 
4.1 Introduction 
The measurement of in vivo protein biomarkers is fundamental to modern 
medicine because it enables clinicians to diagnose patients and monitor their 
response to treatment based on quantitative molecular information.  In the 
emergency room where a patient’s condition can devolve rapidly due to acute 
illness or trauma injuries, there is a great need for fast-reporting protein sensors.   
Coagulopathy describes a class of medical conditions where the normal 
coagulation response has become dysfunctional, often arising as a complication to 
traumatic injury cases[42].  Due to significant blood volume loss as well as 
biochemical changes from distress (acidosis, hypothermia), the composition of a 
patient’s blood can be greatly altered from equilibrium, leading in some cases to 
excess thrombogenic responses, and in other cases, uncontrolled bleeding[42],[92].  
The standard methods for monitoring coagulopathy are prothrombin time (PT, time 
for a plasma sample to clot when activated by tissue factor) and 
thromboelastogram (TEG, viscoelastic measurement of clot strength)[92],[43].  
Although these assays are relatively rapid, they require the labor of a skilled 
technician, which limits the frequency at which patients can be reassessed.   
 
At the date of compiling this thesis, June 2017, this work is still in progress. The 
contents are thus presented as preliminary results. 
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Enzyme-linked immunosorbent assay (ELISA) for coagulation factors is practiced 
less commonly because the turnaround time averages ~2 hours[44], and thus cannot 
provide the temporal resolution (~15 m)[93] needed for emergency intervention 
procedures.  
Previously in our group, aptamers have been developed into rapid-response 
electrochemical “aptasensors” which reported in real-time the in vivo concentrations 
of Doxorubicin injected into a live rat[48] (also see section 1.6).  The microfluidic 
electrochemical detector for in vivo continuous monitoring (MEDIC) reports changes 
in small molecule target concentrations within minutes, requires no externally 
applied reagents or operator labor, and measures directly in whole blood for real-
time reporting[48].  We sought to expand the platform for the detection of protein 
biomarkers, which we called Protein MEDIC (PMEDIC).   
In this work, we built PMEDIC to continuously monitor α-thrombin, a key 
biomarker in the coagulation cascade which reacts with fibrinogen to produce 
clots[94].  We demonstrated continuous aptasensor measurement of arbitrarily 
fluctuating concentrations of thrombin under microfluidic flow. We optimized fluid 
flow conditions to show detection of purified α-thrombin spiked into pool normal 
plasma (PNP).  Finally, we generated native, activated thrombin by introducing 
tissue factor into PNP, and successfully tracked its in situ generation in real-time.  
PMEDIC could enable direct monitoring of coagulopathy as well as patient 
response to therapy via quantitative measurement of native protein biomarkers.  In 
combination with MEDIC, which monitors the body’s metabolism of input 
medications, this creates the opportunity for closed loop personalized medicine. 
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4.2 Results and Discussion 
4.2.1 Principle and Design of PMEDIC 
The PMEDIC platform consists of three modules which enable real-time 
thrombin generation and measurement: an electrochemical aptasensor, a sample 
pre-treatment cocktail, and a selective sheath flow delivery system.  These modules 
are housed within a chip device containing a single microfluidic chamber which 
serves as the electrochemical measurement readout cell.  The chip is constructed 
from glass and PDMS layers using standard microfabrication techniques.  The 
electrochemical cell within the chamber consists of Au counter, reference and 
working electrodes.  Currently, there is a sample input and and a buffer input line, 
and in the future, we plan to install an additional mixer module to apply the pre-
treatment cocktail to the sample before encountering the chip, so as to enable a 
continuous flow of pre-treated sample volume. 
The electrochemical aptasensor probe is the central module of the PMEDIC 
platform (Scheme 4.1A). The probes are self-assembled onto the integrated 
electrodes where they undergo reversible structure-switching in response to binding 
thrombin. The probes are modified at the 3’ end with a methylene blue (MB) redox 
reporter which produces a Faradaic current when interrogated by the potentiostat.  
The value of the output current is determined by the equilibrium probability of the 
aptamer-bound MB reporter striking the surface of the Au working electrode[95].  In 
our system, the thrombin binding aptamer (TBA), switches between a relatively 
unstructured DNA strand to a highly structured G-quadruplex when bound to target, 
thereby changing the electron transfer rate[47].  
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Scheme 4.1. Principle and design of PMEDIC platform. A) Electrochemical aptasensors provide 
reagentless, instantaneous readout of thrombin concentration change. B) Sample pretreatment 
cocktail prepares biological samples for long-term continuous monitoring. C) Optimized continuous 
diffusion filter prevents electrode fouling via a protective buffer sheath which screens out cells, 
platelets, and high molecular weight proteins. 
 
Although single-use electrochemical TBA sensors have previously been 
demonstrated in serum[47], accurate continuous monitoring applications have not 
been possible due to several factors.  First, the formation of physical clots disrupts 
microfluidic flow, making it impossible to accurately assign measurements of 
concentration to the correct point in time.  Second, antithrombin III (ATIII), a native 
thrombin inhibitor present in uM concentrations in blood[96] rapidly binds free 
thrombin to produce thrombin-antithrombin III (TAT) complex[97] which is not 
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detectable by TBA, thereby reducing the magnitude of our target signal.  We 
designed a novel pre-treatment cocktail consisting of Argatroban, EDTA, and 
Streptokinase to address these concerns (Scheme 4.1B). 
Another challenge unique to continuous monitoring of unprocessed 
biological media is the phenomenon of “bio-fouling”, where cell matter and proteins 
will irreversibly adsorb to the aptasensor probes over time and kill their 
functionality[98].  The MEDIC platform designed a continuous-flow diffusion filter 
(CDF) tuned to exclude large particles and proteins, but which permitted high 
diffusivity small molecule targets to reach the aptasensor[48].  For our new system, 
we took advantage of the fact that thrombin is a relatively spherical and small 
molecular weight protein with relatively high diffusivity[99].  We relaxed the selectivity 
of the CDF to permit a fraction of high diffusivity proteins to reach the aptasensor 
(Scheme 4.1C).  
 
4.2.2 The electrochemical thrombin aptasensor 
For the design of the electrochemical thrombin aptasensor, we chose the 
Bock-15 TBA because of its demonstrated high specificity compared to serum 
albumin and chymotrypsin[47] (see 4.4.1, Reagents).  The Bock-15 TBA was 
modified at its 3’ end with a MB redox reporter and at its 5’ end with a thiol linker.  
The thiol linker provides for the formation of Au-thiol covalent bonds to functionalize 
the aptasensor to the Au electrode surface[47].  After we functionalized the Au 
electrodes with the TBA sensors, we passivated the surface with hexanethiol.  
Via continuous microfluidic delivery, we pulsed increasing concentration 
steps of purifed α-thrombin in buffer and measured the electrochemical current 
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response (Figure 4.1). At 50, 100, and 500 nM thrombin, we obtained 300, 350, and 
450% signal gain, respectively (Figure 4.1). Next, we pulsed decreasing 
concentration steps of thrombin and observed complementary decreases in signal 
(Figure 4.1). All samples were delivered continuously and measurements were 
taken in real-time.  These results demonstrate that our system can monitor a 
dynamically fluctuating concentration of thrombin and that these changes can be 
resolved rapidly (~5-10 minutes).  We note that the device equilibrates to decreases 
in concentration somewhat more slowly and this is thought to be due to multivalent 
binding effects[100] slowing the off-rate (see Chapter 5). 
 
 
 
Figure 4.1. Continuous electrochemical measurement of purified α-thrombin dissolved in buffer.  The 
device is able to rapidly report dynamically fluctuating thrombin concentrations. 
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From these curves, we were also able to estimate the approximate linear 
range to be 0-30 nM and the binding affinity (Kd) to be ~30 nM. Previously, we have 
measured the Kd of TBA in solution using a fluorescence bead binding assay to be 
~0.7 nM (Figure 4.2), which agrees with literature values[101].   The decrease in 
affinity when functionalized onto the Au electrodes in our device was not 
unexpected since TBA was selected to perform its function in solution.  By 
anchoring the 5’ end to a surface, TBA has reduced degrees of conformational 
freedom and decreased affinity for thrombin.  In the future, we believe that it would 
be beneficial to select for new thrombin binding probes whose affinity for thrombin 
will not be reduced by functionalization onto a surface.  A promising possibility is 
the use of particle display SELEX, where the DNA selection library is already 
affixed to the surface of a bead and then subjected to selection pressure[85].  
However, for the purpose of our current experiment, we decided that it would still be 
possible to demonstrate the advantages of the PMEDIC system with a thrombin 
aptasensor with Kd ~30 nM. 
 
Figure 4.2. Fluorescence bead-based binding assay of TBA in solution. We measured the Kd to be 
0.70 nM +/- 0.1, which agrees with typical literature values which report the Kd of TBA to be between 
1-10 nM[85]. 
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4.2.3 Specificity of PMEDIC sensor 
 The PMEDIC sensor is highly specific for free α-thrombin, which is hugely 
advantageous for direct detection in unmodified human plasma and/or blood.  
While human plasma and/or blood contains an immense variety of off-target 
molecules, we were specifically concerned about two thrombin-related species: 
prothrombin (PT) and thrombin-antithrombin III (TAT) complex.  Prothrombin is a 72 
kD[102] protein comprised of two units of α-thrombin bridged by covalent bonds[103].  
In the uncleaved state, prothrombin is inactive and does not catalyze the formation 
of fibrin clots[103]. Cleavage of prothrombin yields two active units of α-thrombin[103].  
Prothrombin exists constitutively as an inactive thrombin precursor at 1.41 uM 
physiologically[104], whereas active thrombin is produced in response to injury in pM 
concentrations[105].  Owing to the high level of similarity between thrombin and 
prothrombin (composition and structure), it was important to demonstrate that 
PMEDIC could discriminate between these two species.  We challenged our 
system with 50 nM of thrombin in the absence or presence of 1.4 uM prothrombin 
and found that both resulted in ~30% signal change, indicating that our sensor was 
highly specific for thrombin recognition (Figure 4.3). Therefore, we reasoned that 
PMEDIC measurements of thrombin in clinical samples would not be obfuscated by 
the presence of prothrombin.   
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Figure 4.3. PMEDIC specifically binds to α-thrombin and is unaffected by the presence of 
physiological levels (uM) of the prothrombin precursor molecule. While the absolute current 
measurement showed a small amount of drift where the baseline signal in buffer drifted from ~45 nA 
to ~42 nA, the signal change in response to thrombin challenge relative to the baseline signal was 
~30% in either the presence or absence of excess prothrombin. 
 
We also challenged our system with 50 nM of purified thrombin, and then 
applied an equimolar amount of antithrombin III into the sample tube (Figure 4.4).  
We observed an ~46% signal decrease in response to the initial 50 nM pulse of 
thrombin which rapidly decayed to baseline signal after the introduction of 
antithrombin III (Figure 4.4).  When we found that TBA could no longer detect 
thrombin when it was complexed to ATIII, we confirmed that ATIII must inhibit 
thrombin at the fibrinogen binding site (Exosite I)[10].   
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Figure 4.4. PMEDIC is unable to detect α-thrombin when it is in complex with its native inhibitor, 
antithrombin III.  Initially, when we injected a 50 nM pulse of thrombin, we observed ~46% signal 
decrease relative to the baseline.  Subsequently, we added an excess molar amount of antithrombin 
III to the source test tube containing thrombin and we observed a rapid return to baseline signal.  We 
reasoned that when TAT complex is formed, antithrombin III blocks the aptasensor recognition site of 
TBA. 
 
We reasoned that we could pursue two possible strategies: (1) develop an 
aptasensor probe against TAT or (2) develop a sample treatment which would 
block TAT complex formation.  While it could be possible to make a TAT 
aptasensor by modifying the the Tasset-29 TBA (which binds Exosite II, the heparin 
binding site)[11], we felt that this strategy had a very long lead time.  Moreover, 
measuring TAT is not as valuable as directly profiling active thrombin.  Importantly, 
the half-life of active thrombin generated by injury is 10-20s before being 
complexed with ATIII (TAT half-life is 3 days)[105].  We realized that it was of 
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paramount importance to measure α-thrombin as it is generated in real-time in 
order to accurately interpret the progress of a patient’s coagulopathy.   
 
 
Figure 4.5. Argatroban (Arg), a commercially available small molecule thrombin inhibitor, 
outcompetes native antithrombin III binding, but still permits TBA to detect purified α-thrombin.  In this 
experiment, we pre-treated human plasma (fibrinogen negative, FNEG) with Arg and established a 
baseline signal.  Next, we spiked in 50 nM of purified thrombin into the source test tube and 
measured ~20% signal decrease.  Since we were able to report a signal change in response to 
thrombin, we reasoned that native antithrombin III in plasma was suitably outcompeted by Arg.  
Finally, we switched the sample stream to plain buffer but we observed a disrupted electrochemical 
signal which we attribute to the formation of physical clots interrupting continuous microfluidic flow. 
 
We investigated a number of commercially available thrombin inhibitors and 
identified Argatroban, a small molecule anti-thrombogenic drug as a potentially 
useful candidate[106].  We performed an experiment where we pretreated human 
plasma with 150 uM Argatroban and then spiked in 50 nM purified thrombin (Figure 
4.5).  We observed a signal decrease of ~20% corresponding to the thrombin 
challenge, suggesting that Argatroban was able to suitably outcompete native 
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antithrombin III present in real human plasma (Figure 4.5). Therefore, we reasoned 
that a pre-treatment with Argatroban is a simple, effective strategy to profile active 
thrombin directly in biological sample. 
We note that we used fibrinogen-negative (FNEG) plasma to conduct this 
experiment.  This is because we anticipated that spiking in a high concentration of 
purified α-thrombin would catalyze the formation of fibrin clots from the fibrinogen 
molecules present in complete human plasma.  We have previously observed that 
fibrin clots will form throughout the tubing and also inside the microfluidic sample 
chamber and can dramatically disrupt microfluidic flow.  FNEG plasma has been 
depleted of the majority of its native fibrinogen, and as such, we hoped that we 
could demonstrate the ability of our device to detect thrombin in plasma with 
minimal disruption of microfluidic flow.  In the experiment above, microfluidic flow 
was steady until t = 450 m, when a clot is likely to have formed, causing the 
electrodes to run dry before buffer flow was restored (Figure 4.5).  Even brief 
interruptions to microfluidic flow can shift the electrochemical signal baseline and 
make it difficult to interpret continuous measurements, so in later sections of this 
chapter, we continued to optimize a pretreatment cocktail which would more fully 
suppress errant formation of disruptive clots (see Section 4.2.5).  
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4.2.4 Detection of purified thrombin in pooled normal plasma 
Previously, we showed that we could detect purified α-thrombin in FNEG 
plasma with reasonable reliability.  But our next challenge was to detect α-thrombin 
in whole human plasma.  We note that in our experiments with FNEG plasma we 
observed non-specific signal decrease due to the presence of plasma directly 
interacting with the aptasensor-modified electrodes.  However, since we were still 
able to detect purified α-thrombin against this background, we decided to test 
whether we could detect it in Argatroban-treated pooled normal plasma (PNP) 
without further modifications or the CDF platform. 
 
 
 
Figure 4.6. Detection of purified α-thrombin in PNP. PNP was first pretreated for 10 minutes with 
Argatroban to prevent the formation of fibrin clots and to prevent signal inhibition by native 
antithrombin III.   
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 We observed that even without implementing the CDF, we were able to 
detect 150 nM of purified α-thrombin directly in PNP as a 250% increase in signal 
compared to buffer baseline (Figure 4.6).  Notably, the PNP appeared not to create 
as significant of an electrochemical signal artifact and after a buffer wash, the 
device appeared to be able to recover its original baseline signal (Figure 4.6).  We 
do not know why some devices are more robust against fouling but we attribute this 
variation to uncontrolled differences in aptasensor and passivation alkanethiol self-
assembly.   From these experiments, we confirmed that purified thrombin could be 
detected directly in biological sample. 
 
4.2.5 Detection of in situ generated native thrombin in plasma 
Whereas all of our previous experiments dealt with the detection of 
commercially obtained, purified, α-thrombin, our next challenge was to generate 
native thrombin directly from PNP and determine if our aptasensor devices could 
detect it.  Tissue factor (TF) is a protein that is typically sequestered by the 
endothelial lining of blood vessels[94].  When injury occurs and damages the blood 
vessel, tissue factor is released into the bloodstream where it activates the 
coagulation cascade in order to close the wound[94].  Although there is not a 
consensus on what the physiological concentrations of TF are in the bloodstream 
during injury, typical laboratory tests and precedent in the literature suggest that 10 
pM of TF is a suitable amount to initiate coagulation in vitro for study[107],[108].   
 85 
 
 
Figure 4.7. In situ generation of native thrombin from PNP.  A) We initiated the coagulation cascade 
with 10 pM of TF, considered a 1X dose, but did not observe a significant signal change.  B) We 
increased the amount of TF to 100 pM (10X) and we were then able to observe 150% signal 
increase, which we believe is due to native thrombin generation. 
 
As such, we performed an experiment where we applied 10 pM (1X dose) or 
100 pM (10X dose) of TF to 1 mL of Argatroban-treated PNP and measured the 
increase in thrombin concentration over time (Figure 4.7).  Surprisingly, initiation 
with 1X TF did not generate a signficant signal change (Figure 4.7).  We believe 
that this is due to the high signal background that arises when measuring directly in 
plasma (see Figure 4.5).  Perhaps under 1X TF conditions, not enough thrombin 
was generated for us to detect a signal change over the plasma background.  We 
increased the dose to 10X TF and then we were able to observe 150% signal 
increase occurring over 20 minutes (Figure 4.7).  Due to batch-to-batch variation in 
self-assembly and the signal background caused by plasma, we are not able to 
calculate the concentration of thrombin generated in these two experiments.  In the 
future, we could explicitly measure this value by performing ELISA measurements 
on this sample, post-experiment.  The main takeaway from this experiment is that 
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we were fairly confident that not only could we generate thrombin from PNP, but 
that we could detect at least a fraction of natively generated α-thrombin with our 
devices. 
However, we recognized that we needed to reduce the background due to 
PNP contact with the electrodes, so we implemented an optimized continuous 
diffusion filter (CDF).  We note that in our experiment with fibrinogen depleted 
plasma, simply equilibrating the chip with plasma caused a ~20% signal decrease 
relative to the baseline in buffer (Figure 4.5).  Since α-thrombin is not present in 
significant quantities in unactivated plasma[105], we surmised that this was a non-
specific signal change in response to the significant protein content of human 
plasma which greatly decreases the dynamic range of detection of the aptasensor.  
Furthermore, the chip sensor never recovered to its initial current baseline even 
after washing in buffer, suggesting that bio-fouling of the sensor occurred (Figure 
4.5).  As we previously alluded to in 4.2.1, the MEDIC system addressed fouling by 
creating a continuous diffusion filter (CDF) where a protective sheath stream is 
stacked between the aptasensor-modified electrodes and the sample stream via 
laminar flow[48].  Ferguson and co-workers tuned the flowrate and the thickness of 
the protective sheath layer to permit only high-diffusivity small molecules to travel to 
the aptasensor-modified electrodes, whereas low-diffusivity interferents such as 
blood cells, platelets, and proteins were unable to diffuse into the detection area 
during the time in which the sample volume traveled through the chip[48].  In the 
PMEDIC system, we reduced the thickness of the protective sheath layer from 125 
μm to 50 μm to permit a fraction of high-diffusivity small proteins to travel to the 
aptasensor-modified electrodes.  We believe that the majority of fouling arises from 
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protein interferents that exist at high concentration in the plasma, namely 
immunoglobulin G (IgG) and human serum albumin (HSA)[109].  Therefore, we 
believed that relaxing the CDF to permit a fraction of small proteins would allow us 
to still detect our target, thrombin, but screen out the majority of fouling proteins. 
We took advantage of the fact that thrombin is a small (36 kD), relatively spherical 
protein, with a hydrodynamic radius of 2.4 nm[99].  The Stokes-Einstein equation, 
therefore, calculates its diffusitivity to be 41.8 μm2/s[99].  In comparison, IgG and 
albumin are typically ~150 kD[27] and ~70 kD non-spherical proteins[111]. 
Furthermore, we note that in our experiments with FNEG plasma, 
microfluidic flow was not disrupted by clot formation for 450 minutes when the 
sample was pretreated with Argatroban (Figure 4.5).  We identified that we needed 
to extend our ability to perform continuous monitoring by adding further 
components to the pretreatment cocktail to suppress fibrin clot formation.  We 
added two more components: EDTA and Streptokinase.  EDTA is a chelating agent 
which removes Ca2+ from solution, a divalent ion binding partner for many 
coagulation factors[94].  Streptokinase is a bacterially derived fibrinolytic – an 
enzyme which breaks down clots[112].   
At this time, we had assembled a complete PMEDIC platform consisting of 
the aptasensor, the pretreatment cocktail, and optimized CDF. Under microfluidic 
sample flow with a protective CDF, we first equilibrated the sample in buffer, then in 
Argatroban-doped PNP (Figure 4.8).  We paused microfluidic flow and applied 1X 
TF for 5 minutes.  Next, we quickly mixed in EDTA and Streptokinase to halt the 
formation of large fibrin clots and re-started sample flow.    We observed an 
excellent  ~35% signal decrease over 3000 s (Figure 4.8). 
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The improved PMEDIC platform demonstrated several novel achievements.  
First, the optimized CDF permitted us to shield the aptasensor-modified electrodes 
from the majority of fouling effects, yet permitted the transport and detection of our 
protein target α-thrombin.  This was evidenced by how the baseline signal in 
plasma was not substantially changed from the baseline signal in buffer.  Second, 
the pretreatment cocktail prevented native inhibitors from diminishing the signal of 
generated thrombin.  In combination with the background reducing effects of the 
CDF, these two innovations permitted us to see a large signal change (~35%) in 
response to 1X TF generated thrombin.  Moreover, the pretreatment cocktail 
prevented the formation of fibrin clots which would have disrupted continuous 
measurement for nearly 2 hours, a time scale which would be relevant for clinical 
applications of this device. 
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Figure 4.8. Demonstration of the complete PMEDIC platform. We equilibrated the device in PNP 
pretreated with Arg.  Although we observed a momentary disturbance in the baseline signal this 
effect settled after 3000 s.  At t = 6000 s, we paused sample flow, spiked in 1X TF for 5 minutes, then 
immediately mixed in the rest of the pretreatment cocktail. We observed ~35% signal decrease in 
response.  
 
4.3 Conclusions 
In summary, we have developed a new platform called PMEDIC which 
enables us to not only generate native thrombin from human plasma, but to 
continuously monitor it in situ.  To the best of our knowledge, this is the first ever 
demonstration of generating and detecting native thrombin in a continuous 
monitoring device.  Previous works in the literature have been limited to the 
detection of commercial, purified α-thrombin and to single-measurement sensors. 
In this work, we showed that the PMEDIC sensor was highly specific for α-thrombin 
and was not sensitive to either its precursor molecule, prothrombin, nor its 
downstream deactived product, TAT.  We designed a novel pretreatment cocktail 
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which amplified our ability to detect thrombin by preventing signal loss due to 
complexation with native inhibitors.  The cocktail was also highly effective in 
preventing the formation of fibrin clots which would have disrupted microfluidic flow 
and thus extended our ability to monitor thrombin continuously to over 100 minutes.   
Finally, we optimized the CDF to permit our target protein to be transported to the 
aptasensor-modified electrodes for detection, but to still screen out the majority of 
bio-fouling blood proteins.  Altogether, PMEDIC has demonstrated potential for 
continuous monitoring of thrombin in the emergency room, which could enable 
closer tracking of coagulopathy and more rapid medical intervention. 
Although PMEDIC has many advantageous attributes, there are remaining 
challenges to address.  While TBA aptasensor has a Kd of ~30 nM, physiological 
levels of thrombin are in the fM – pM range[105].  We believe that it may be possible 
to achieve more relevant levels of sensitivity by re-designing the HD1-22 bivalent 
thrombin sensor into an electrochemical sensor, since it has a reported Kd of <1 
pM[105].  Another issue of concern is that our optimization of CDF permissivity is a 
technique that is only suitable for the detection of high-diffusivity protein targets, 
which will not be applicable if the protein of interest is of medium to large size.  It is 
of great importance to consider other strategies not based on a diffusion gradient to 
protect the electrodes from fouling.   
In the future, it may be of interest to reconceive the fundamental premise of 
how to achieve continuous monitoring of biomolecules.  In this work, we have 
developed many innovations to prolong the usable lifetime of a single device, which 
provides reporting of concentration change every ~5 minutes.  But we reiterate that 
in consultation with Dr. Mitch Cohen, M.D. (UCSF), a world expert on coagulopathy 
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and emergency room medicine, measuring thrombin every 15-30 minutes would 
already be sufficiently fast to provide clinical benefit.  In future works, we envision a 
platform based on an array of single-use aptasensor chips without complicated 
protective systems.  Each single-use chip would be automated to run a self-
calibration against a standard curve of concentrations and then take a single 
measurement of thrombin concentration and never be used again since subsequent 
measurements would be less accurate due to fouling.  A timer system for the array 
would then wait for 15 minutes, and then activate the next chip in the array to 
repeat these actions.  Given that our sensor devices can be made relatively 
inexpensively and in bulk (~100 chips in one batch), construction of an array of 
these chips is practical. 
 
4.4 Experimental Section 
4.4.1 Reagents 
The probe (5′-HS-(CH2)6-TAAGTTCATCTCCCCGGTTGGTGTGGTTGGT-
(CH2)2-MB-3′) with 3’ C6-linked thiol and 3’-linked methylene blue label was 
synthesized by Biosearch Technologies (Petaluma, CA).  The FAM modified 
aptamer, (5′-FAM-TAAGTTCATCTCCCCGGTTGGTGTGGTTGGT) was produced 
by Integrated DNA Technologies (Coralville, IA). Tris-(2-carboxyethyl) phosphine 
hydrochloride (TCEP) was obtained from Invitrogen (Carlsbad, CA). 6-
mercaptohexanol was purchased via Sigma-Aldrich (St. Louis, MO).  Purified 
human α-thrombin, prothrombin, antithrombin III, and recombinant tissue factor 
used for this study were produced by Haematologic Technologies Inc (Essex 
Junction, VT).  Fibrinogen-negative and pooled normal plasma was obtained from 
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BioreclamationIVT (Baltimore, MD).  Argatroban, Streptokinase C, EDTA as well as 
reagents for making reaction buffers were all purchased from Sigma-Aldrich (St. 
Louis, MO). Magnetic carboxylic acid Dynabeads were purchased from 
ThermoFisher Scientific.  Tygon tubing was obtained from Sigma-Aldrich. HEPES 
buffered saline was obtained from Sigma-Aldrich. The pretreatment cocktail was 
prepared in DI as follows: 150 uM Argatroban, 1.5 mg/ml EDTA, 100 IU/ml 
Streptokinase. The high salt phosphate buffer (HSPB) used for functionalizing 
devices with probes comprised: 100 mM sodium phosphate, 1 M NaCl, 1 mM 
MgCl2, pH 7.4.   
 
4.4.2 PMEDIC Sensor Preparation 
 
Scheme 4.2. Device architecture and fabrication.  
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PMEDIC chips were assembled from four separately fabricated modules 
consisting of the electrode substrate, the sample chamber layer, the buffer sheath 
chamber layer, and the fluidic via substrate.  The electrode substrate was patterned 
with gold reference, counter, and working electrodes onto 4-inch-diameter 750-um-
thick Borofloat glass wafers (University Wafer, Boston, MA) using standard 
photolithography and lift-off processes.  A transparency mask (Grayphics, Santa 
Barbara, CA) was used for contact photolithography and e-beam evaporation 
deposition in a VES 2250 evaporation chamber (Temescal, Livermore, CA) 
deposited 20 nm titanium for adhesion and 180 nm of gold onto the wafers.  
Afterwards, the wafers were immersed in acetone for 1 hour for lift-off, followed by 
isopropyl alcohol and deionized water washes.  Samples were dried with nitrogen.  
The two chamber layers were each constructed from 50-um-thick double sided tape 
(3M) with the channel design cut with a sign-cutting tool (CE5000-60, Graphtec, 
Santa Ana, CA).  The fluidic via substrate was prepared by drilling eyelet holes into 
a second glass wafer with a 1.1-mm-diameter diamond drill bit (Tripple Ripple, 
Abrasive Technology, Lewis Center, Oh) using a CNC mill (Flashcut CNC, San 
Carlos, CA).  The electrode substrate and fluidic via substrate were diced into 
individual chips (ADT 7100 Dicing Saw) and washed with ACE/ISO/DI procedures. 
The four device layers were manually assembled under an optical microscope in 
order to precisely align the sample chamber layer and the buffer sheath chamber 
layer before adhesion. Fluidic ports were epoxied over the vias to provide one 
buffer sheath inlet, one sample inlet, and one outlet. The finished chip measured 30 
mm X 7.5 mm, with a sample chamber volume of ~20 uL. 
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4.4.3 PMEDIC Electrode Cleaning and Functionalization 
After device assembly, the gold working electrodes in each chip was 
electrochemically cleaned via cyclic voltammetry performed on a Emstat3 mini-
potientostat (Palmsens, Germany) using 50 mM H2SO4, with 12 potential sweeps 
ranging from -0.8V to 1.0V applied at 0.1 Vs-1 with a sample interval of 0.001V and 
10 uA sensitivity.  Afterwards, cleaned chips were rinsed with DI water. At this time, 
the chips were electrochemically clean and ready for modification with DNA probes. 
To activate the thiolated DNA probes, we incubated them in 100 mM TCEP 
at room temperature for 1 h to reduce disulfide bonds, then diluted to 1 uM in 
HSPB.  The activated probe solution was loaded into the electrochemically cleaned 
chips and was incubated for 1 h in the dark at room temperature to allow the probes 
to form covalent Au-thiol bonds and self-assemble on the electrode surface.  
Thereafter, the functionalized electrode surfaces were rinsed in DI and then 
passivated with 3 mM 6-mercaptohexanol in DI for 1 h in the dark at room 
temperature.  After these processes, the chips were rinsed for a final time in DI, and 
will hereafter be referred to as sensors.  The sensors can be stored indefinitely in 
HBS buffer at 4°C. 
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4.4.4 Time-Course Response Experiments 
We used square wave voltammetry (SWV) for monitoring the MB redox 
current during thrombin measurements.  The following SWV parameters were used 
(values relative to Au reference electrode): 0.08 V initial voltage, -0.2 V final 
voltage, 0.001 V increment, 0.03 V amplitude, 100 Hz frequency, 0.11 s sample 
time and autosensitivity. Under continuous microfluidic flow, we would measure the 
MB redox current in response to challenges with thrombin dissolved in HBS buffer 
or in plasma.  To switch to a different concentration challenge or sample, we simply 
transferred the tubing connected to the sample inlet into a new test tube.  All 
plasma samples were subjected to the pretreatment cocktail before being input into 
the chip for testing. 
Device flow was controlled via syringe pump (PHD 2000, Harvard Apparatus, 
MA).  We optimized the CDF barrier parameters to permit thrombin to cross the 
buffer sheath.  To do this, we maintained a 1:1 flow ratio for the buffer stream and 
the sample stream.  One syringe pump was connected to the output port, 
withdrawing at a rate of 40 ul/mn.  A second syringe pump containing HBS was 
connected to the buffer port and pushed HBS into the chip at 20 ul/mn.  The 
sample port was connected to open-ended Tygon tubing which could be switched 
between different sample test tubes. 
 
4.4.5 Fluorescence bead-based assay of Kd 
We measured the solution Kd of the thrombin aptasensor by incubating a 
range of concentrations of FAM-labeled thrombin aptasensor ssDNA with thrombin-
coated beads for 1 hour at room temperature with gentle rotation.  These samples 
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were then washed 4X using a magnetic particle concentrator (Invitrogen), and the 
remaining bound DNA was eluted from the beads by thermal melting at 95C in a 
heat block for 10 m.  The amount of fluorescence in the elutiosn were measured 
with a microplate reader (TECAN 1000) and the values were fit to a saturation 
binding curving using nolinear regression, assuming 1:1 binding kinetics, with Origin 
software (OriginLab). 
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Chapter 5. Thermal regeneration of electrochemical aptasensors for 
rapid thrombin detection 
5.1 Introduction 
In Chapter 4, we described a platform for continuous in situ monitoring of α-
thrombin protein in human pooled normal plasma.  We had previously discussed 
the importance of continuous biomarker monitoring, as it gives clinicians the ability 
to rapidly observe changes in a patient’s disease state and provide medical 
intervention.  In particular, we have identified that the treatment of trauma-induced 
coagulopathy which often arises in the emergency room can greatly benefit from 
continuous monitoring of serum levels of α-thrombin protein as a marker for a 
hypercoagulatory state.  In consultation with a medical expert on coagulopathy, Dr. 
Mitch Cohen (UCSF), we have identified that a sensor measuring updated 
concentrations of thrombin every 5-15 minutes would offer the most benefit to 
clinicians.  Moreover, it is also of great importance to develop thrombin sensors with 
greater sensitivity, so that we can approach our ultimate goal of measuring in vivo 
concentrations (fM – pM)[105] of thrombin directly in whole blood. 
The method of detection we employed in the PMDEDIC platform  method 
was an electrochemical aptasensor for thrombin.  Aptasensors are an equilibrium 
detection method: the target and the sensor reach a binding equilibrium over a 
period of time, at which point the electrochemical readout reflects the target 
concentration in solution[47].    
 
At the date of compiling this thesis, June 2017, this work is still in progress. The 
contents are thus presented as preliminary results. 
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The time to equilibration represents the limit for how quickly changes in 
target concentration can be reported.  Empirically, we observed that our thrombin 
aptasensor devices require ~2-5 minutes to equilibrate to increased concentration 
of thrombin, whereas decreases in concentration require at least 2-fold more time 
to fully equilibrate (see Figure 4.1).  In our aptasensor devices, possibly due to a 
multivalent surface effect[113-115], we have observed that up to 50% of thrombin 
effectively stays permanently bound to the device surface (>50 m for clearance) 
(Figure 5.1).   Although a reduced dissociation rate is advantageous for 
sensitivity[116], this effect is problematic because future measurements are 
obfuscated by still-bound thrombin. 
 
Figure 5.1. A typical thrombin pulse association and dissociation test on an aptasensor chip.  After 
equilibration for 5 minutes in buffer (flowrate 10 ml/hr), we challenged the chip with 100 nM of purified 
thrombin and observed ~40% decrease in electrochemical current after equilibration for 8 minutes.  
Next, we flowed plain buffer through the chip once again to measure thrombin dissociation and found 
that the signal was restored to only half of the initial current after more than 30 minutes of 
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observation, indicating ~50% of thrombin is still bound to the aptasensor chip.  These behaviors are 
typical of many chips we produced where thrombin association is reasonably rapid, but dissociation is 
so slow that future measurements are obfuscated by still-bound thrombin. 
 
We have developed a simple but powerful strategy to improve accuracy and 
speed of thrombin aptasensor measurement through thermal regeneration of the 
sensor chip (Scheme 5.1).  In our scheme, the aptasensor starts out in its native, 
unbound state (Scheme 5.1A) and then is challenged by an infusion of new 
sample. The aptasensor probes bind to thrombin in the sample and equilibrate to 
report the concentration (Scheme 5.1B).  Next, an attached mini-thermoelectric 
cooler (TEC) element raises the temperature of the chip to 70°C, melting the 
aptamer and releasing thrombin, which is washed away by the continuous 
microfluidic flow (Scheme 5.1C). Previously, some studies have found that the 
melting temperature of thrombin aptamer is as high as 51°C in the presence of 
buffers with monovalent ions, so we tested a range of temperatures between 51-
95°C to determine the minimum melting temperature required for our system, which 
we thereafter determined to be 70°C[117]. Then, the mini-TEC element cools the 
system to 25°C, re-folding the  aptasensor, where it is unbound and ready to 
measure again.  As such, we are able to update the thrombin concentration more 
frequently by leveraging only the more rapid association mode.  Moreover, thermal 
regeneration of the system completely removes any bound thrombin, allowing for 
an accurate measurement of concentration each time. 
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Scheme 5.1. Continuous thermal regeneration and measurement of a thrombin aptasensor. (A) The 
sensor chip  in its native unbound state.  (B) When challenged by a new sample volume, the probes 
bind to thrombin, undergoing a conformation change that reduces the electrochemical current and 
reports the thrombin concentration.  (C) The sensor chip undergoes thermal regeneration at 70°C 
where the aptasensor DNA is melted and loses its affinity for thrombin, thus regenerating the initial 
state (A).  This scheme also illustrates the time constraints on how quickly the system can be cycled.  
There are well-defined minimum times for the system to ramp to 70°C, soak at 70°C to fully 
thermalize the probes, ramp down to 25°C, and soak at 25°C during binding equilibration and 
measurement.  
 
Previously in the literature, there have been other approaches to regenerate 
aptasensor chips for multiple measurements including washes with denaturating 
salts[118], detergents[118] and chelating agents to remove supportive ions[119] and 
these approaches are effective for the regeneration of single use chips.  Whereas, 
our system is specifically optimized for rapid, continuous measurements because 
regeneration is performed by an external mini-TEC element which cycles the 
temperature in the chip automatically, without disrupting continuous microfluidic 
delivery of new sample volume.  In this work, we showed that we are able to update 
the concentration of thrombin in a continuous aptasensor within ~5 minutes and 
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that the device has been completely regenerated to its unbound state for each new 
measurement. 
 
5.2 Results and Discussion 
5.2.1 Design of the thermal regeneration system 
The assembly of our apparatus was a straightforward modification of the 
thrombin aptasensor device where we mounted the microfluidic chip containing the 
aptasensor-functionalized probes on top of a thermoelectric cooler linked to a 100 
Ω platinum resistive temperature detector, a DC power supply, and a PID 
temperature controller (Figure 5.2).  Thermal contact was maintained between the 
chip and the TEC by thermal paste.  The aptasensor chip was connected via a 
modified PCBI connector to a potentiostat which provided the electrochemical 
readout.   
 
Figure 5.2. Photograph of the thermal regeneration apparatus mounted with an electrochemical 
thrombin aptasensor. 
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5.2.2 Optimization of thermal regeneration and  measurement cycle 
time 
As noted in Scheme 5.1, our goal was to minimize the time for a complete 
cycle of thrombin measurement and thermal regeneration.  From previous 
measurements for PMEDIC, we determined that 2.5 minutes was a suitable amount 
of time for the probes to come to ~90% signal equilibrium for a 50 nM pulse of 
thrombin (see Figure 4.1).   Since physiological concentrations of thrombin are 
lower than 50 nM[105] and would require less time to equilibrate, we set the “binding 
equilibration time” for our system to 2.5 minutes.  
For thermal regeneration, we needed to minimize the ramp times to 70°C 
and 25°C, respectively.  We tuned the PID parameters of the controller to balance 
speed with stability of temperature ramping.   Although we wanted to achieve target 
temperature as quickly as possible, we were concerned that temperature overshoot 
past 70°C might damage the probes.  We used the PID “autotune” function and 
found that reasonable parameters for P = 43, I = 14 s, D = 19 s.  Under these 
settings, ramp-up time to 70°C was ~30 s and ramp-down time to 25°C was ~60 s.  
To determine the soak time necessary to melt the probes, we performed an 
experiment where we continuously measured the electrochemical current of the 
device in plain buffer while ramping the temperature between 25°C and various 
melting temperatures between 74°C – 82°C (Figure 5.3).  We found that at 25°C, 
the baseline measured current was ~0.05 uA, but when the chips were fully 
thermalized at high temperature, the probes read ~0.22 uA due to the added 
thermal energy (Figure 5.3).  The probes achieved maximum signal due to thermal 
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energy within ~60s (including the time needed for the TEC to ramp up), therefore 
we determined that the necessary soak time at 70°C was ~30s (Figure 5.3).  
 
Figure 5.3. Determination of soak time needed for complete chip thermalization to target 
temperature. For all tested temperatures, the chip thermalized within ~60s to the target temperature 
when starting from 25°C. 
  
We performed three cycles of time-optimized thrombin measurement and 
thermal regeneration and found that the device was thermally robust and accurately 
reported the thrombin concentration (Figure 5.4).  First, we equilibrated the system 
to plain buffer (0 nM thrombin) for 60s, then we challenged the system with 50 nM 
thrombin and equilibrated for 140s and observed a ~32% signal decrease (Figure 
5.4).  Next, we performed the thermal regeneration cycle which took 100 s total 
including temperature ramp times and soak time. Afterwards, we re-measured the 
current readout corresponding to plain buffer and found it to be equivalent to our 
initial signal.  We repeated this cycle one more time to show reproducibility and 
indeed, we found that the second pulse of 50 nM thrombin showed similar 
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equilibration times and change in current (Figure 5.4).  Under these conditions, the 
concentration of thrombin can be accurately and rapidly updated every ~5 minutes.  
Given that in vivo serum concentrations of thrombin are typically in the fM- pM 
range[105], our setup will be able to respond even faster to lower concentrations of 
thrombin, making the temporal resolution of our system well-suited for future clinical 
applications. 
 
Figure 5.4. Time-optimized continuous measurement and regeneration of the aptasensor device.   
With our optimized system, the thrombin concentration can be accurately and reproducibly measured 
every ~5 minutes. 
 
 105 
 
5.2.3 Batch-to-batch variation in device performance 
Although our initial devices proved to be robust for multiple cycles of 
measurement and thermal regeneration, in later experiments, we encountered 
significant challenges producing devices with reproducible behaviors.   A significant 
number of devices tested showed drift in the baseline signal (0 nM thrombin in plain 
buffer) after a single thermal regeneration cycle.  For example, we typically found 
that while the signal change in response to a pulse of 100 nM thrombin caused a 
~22% decrease in current, the buffer baseline current could drift up to 10% after a 
regeneration cycle (Figure 5.5A).  The signal drift was large enough to make 
multiple consecutive thrombin measurements difficult to interpret, and as such, 
would make continuous clinical monitoring of thrombin very challenging.   
In order to confirm that the shift in baseline signal was from thermal cycling, 
and not due to insufficient removal of bound thrombin, we flowed plain buffer 
through the chip, subjected the device to 12 cycles of thermal regeneration, and 
then applied a 100 nM pulse of thrombin to assay the performance (Figure 5.5B).  
We observed that each cycle of thermal regeneration decreased the baseline signal 
a small amount, which suggests that the decreasing baseline signal is caused by 
deterioration of the chip from heating.  The 100 nM thrombin pulse at the end of the 
experiment was a control to show that the device was typical and indeed, it 
produced expected behaviors: a ~40% decrease in current and slow dissociation 
from the probes after being washed with plain buffer. 
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Figure 5.5. A) A thrombin aptasensor device showing ~10% baseline signal drift after 1 cycle of 
thermal regeneration.  Although the device still produces a similar current change in response to a 
100 nM pulse of thrombin, the shift in absolute currents would make continuous in vivo monitoring 
difficult to interpret.  B) We found that 12 cycles of thermal regeneration in plain buffer could cause 
~10% baseline signal drift, which suggests that the decreased baseline signal arises from thermal 
damage, not from still-bound thrombin on the sensor surface.  Interestingly, a 100 nM thrombin pulse 
at the end of this experiment still showed reasonable current change (~40% decrease), which 
indicates that the chip still functions well as a sensor, relative to the new baseline current.  
  
Nominally, all devices were produced using the same protocol: thin film Au 
deposition onto glass wafers, followed by self-assembly of thiol-modified 
aptasensor probes and a C6 alkanethiol passivation monolayer onto the Au 
electrode surface (see section 5.4.3).  We decided to try to track down the source 
of inconsistent device performance. 
We theorized that the E-beam evaporator we used to deposit thin film gold 
for our electrodes could have a contaminated Au source, so we used X-ray 
photoelectron spectroscopy (XPS) to determine if there were unexpected 
contaminants.  However, XPS results showed that there was not a significant 
presence of unexpected elements (Figure 5.6).  The only elements detected in 
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significant quantities were Au from our thin film deposition; Si, O, and B from the 
borosilicate glass wafer;  and Sn which is used in float glass production[120]. 
 
Figure 5.6. XPS of aptasensor device electrode shows that there are no significant unexpected 
contaminants. The main components detected are Au from our deposition process, Si and O (from 
the glass wafer), and Sn and B which are typical trace elements in glass wafers[120].  
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Having ruled out effects due to a contaminated Au source, we theorized that 
variation in the quality of the C6 passivation layer could affect the thermal 
robustness of devices.  In aptasensor devices, it is thought that C6 chains help to 
space out individual thrombin probes to prevent entanglement, and that they also 
play a role in supporting proper folding of the aptamer[121][122].   Moreover, it is also 
thought that interchain interactions between alkanethiols raises the melting 
temperature of functionalized surfaces[123].  We theorized that there could be 
variation in C6 self-assembly due to day-to-day variation of environmental 
conditions.  As such, we increased the reaction time for C6 functionalization from 1 
hour to overnight so that the system would have longer to come to equilibrium. We 
did not observe significant improvement in the device tolerance for thermal 
regeneration (Figure 5.7).  We believe that thermal regeneration of heat-intolerant 
batches of aptasensors results in probe and/or alkanethiol loss[123].  In contrast, a 
denaturing salt wash (guanidine hydrochloride, GHCl) regenerated the aptasensors 
with no apparent changes to baseline signal and showed a normal response to a 
100 nM thrombin pulse. 
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Figure 5.7. After overnight C6 treatment, thermal cycling still appears to be fundamentally destructive 
to heat-intolerant batches of aptasensors.  The drift in absolute current suggests loss of thrombin 
probes and/or C6 passivation molecules.  Whereas washing with GHCl appears to have a non-
destructive regenerative effect. 
  
We explored several other avenues to standardize the thermal tolerance of 
our aptasensor devices including slowing down the rate of Au thin film deposition 
and using excess thrombin probes for functionalization.  However, these efforts did 
not appear to improve thermal tolerance of the devices either.  We were not able to 
definitively isolate the cause of variation in aptasensor thermal tolerance, so we 
decided to move on to other projects.  
 
5.3 Conclusions 
In summary, we have developed a new strategy to improve the speed and 
accuracy of continuous thrombin monitoring.  In this work, we show that it is 
possible to thermally regenerate an aptasensor chip via a programmed mini-TEC 
element, enabling us to measure the concentration of thrombin every ~5 minutes. 
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Our system is advantageous for continuous monitoring applications because it 
requires no externally applied reagents or discretized wash steps and the 
measurement/regeneration cycle is programmed to act automatically.   
Although the principle idea of this project holds merit, we encountered 
significant challenges in producing consistently thermally robust devices.  We found 
that although the sensitivity and dynamic range of thrombin aptasensors was 
preserved, thermal cycling could shift the baseline signal significantly, which would 
obfuscate continuous monitoring in vivo.  We determined that there were no 
unexpected contaminants in the Au electrodes, and that differences in C6 self-
assembly were unlikely to affect thermal tolerance.  Since the DNA component of 
aptasensors is known to be thermally stable at  far higher temperatures (in PCR, 
oligos are repeatedly heated to 95C without damage), we think that the most likely 
cause of probe and/or C6 loss is thermal damage to the Au-thiol bonds which 
anchor these components to the electrode[123].  Going forward, we believe that 
exploring alternative chemistries to link the probes and C6 molecules to the 
electrodes which are more thermally robust may be the key to making this platform 
work consistently.   
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5.4 Experimental section 
5.4.1 Reagents 
Since the devices produced for this project were identical those produced for 
the PMEDIC project, the reagents used were identical.  Please see section 4.3.1. 
 
5.4.2 Chip fabrication 
Please see 4.3.2.  
 
5.4.3 Electrode cleaning and sensor preparation 
Please see 4.3.3. 
 
5.4.4 Microfluidic sample delivery 
Device flow was controlled via syringe pump (PHD 2000, Harvard Apparatus, 
MA).  Since the experiments for thermal regeneration were only performed in 
buffer, we did not need to set up a CDF.  As such, the chip was prepared with 1 
input and 1 output port, where the buffer sheath port was plugged shut.  The 
syringe pump was connected to the output port and operated by withdrawing 10 
ml/hr of sample volume.  The input port was connected to open-ended Tygon 
tubing which could be switched between different test tubes containing various 
concentrations of purified thrombin dissolved in buffer (0-100 nM). 
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5.4.5 Voltammetry and thermal regeneration experiment 
We measured the MB peak currents of the aptasensors in the presence of 
either plain buffer (HBS, 0 nM thrombin) or pulses of 50 or 100 nM purified α-
thrombin dissolved in HBS (Haematologic Tech, Essex, VT) under continuous 
microfluidic flow.  
Thermal regeneration was perfomed by mounting the aptasensor chip onto a 
thermoelectric cooler (TEC, Custom Thermoelectric, MD) connected to a 100 Ω 
platinum resistive temperature detector (RTD, Minco, MN), a DC power supply, and 
a PID temperature controller (Omega Engineering, CT).  The chip was subjected to 
temperature cycling between 25C and 70C, with a 2.5 m soak time at 25C and a 
30s soak time at 70C.  The rate of temperature ramping between these two target 
temperatures was maximized to optimize for the fastest rate of thermal 
regeneration and measurement cycling.  We used the autotune function on the PID 
controller to balance speed of temperature ramping with temperature stability and 
minimal temperature overshoot (P = 43, I = 60 s, D = 19 s) .  Good thermal contact 
was maintained between aptasensor chips and the TEC via thermal compound 
(Arctic Alumina, Arctic Silver, CA).  Time-course continuous electrochemical 
measurements were taken only during the 25C sensor equilibration time, alternating 
with a no-read period during thermal regeneration.  A single optimized 
measurement-and-thermal-regeneration cycle was completed in ~5 minutes.  
Electrochemical measurements were performed on a Emstat3 mini-
potentiostat (Palmsens, Germany).  Square-wave voltammetry (SWV) was used for 
monitoring the changes in MB redox current during thrombin measurement 
experiments.  Typical SWV parameters used are as follows: 0.08V initial voltage, -
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0.20 V final voltage, 0.001 V increment, 0.03 V amplitude, 100 Hz freqeuncy, 0.11 s 
sample period, and auto sensitivity.  A custom Python script was written to 
synchronize the PID temperature controller and the potentiostat in order to alternate 
between electrochemical measurements and thermal regeneration (no-read 
period). 
 
5.4.6 X-ray photoelectron spectroscopy 
X-ray photoelectron spectroscopy was performed on unassembled, un-
functionalized Au electrode substrates using a Kratos Ultra XPS (Kratos Analytical 
Limited, Kyoto, Japan). 
 
5.4.7 Denaturing salt wash regeneration of chips 
6.0 M guanidine hydrochloride was manually injected into the input port of 
chips with a 1 mL syringe several times to displace previous sample volumes.  The 
chip was incubated with GHCl for 5 m, rinsed with DI, and then reattached to the 
syringe pump to restart continuous measurement.  
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Chapter 6.  Conclusion 
The field of precision medicine encompasses myriad exciting research 
movements across multiple disciplines and in this thesis, we have presented 
several projects addressing the need for controlled drug delivery and real-time 
molecular diagnostics.  Controlled release technologies provide for more 
sophisticated manipulation of the timing and targeting of an active drug payload, 
thereby reducing side effects and concentrating the efficacy of dosage at the site of 
illness.  In parallel, the development of real-time diagnostics can give quantitative 
feedback about not only the instantaneous blood concentration of a drug but also 
potentially, the physiological response of the patient.  As such, real-time diagnostics 
provide real-time insight into the efficacy of treament. These technologies, 
therefore, are partners in making precision medicine the new standard of 
healthcare.   
 
6.1 Final comments on PADNA and PGSA 
PADNA and PGSA were projects with the shared objective of controlling the 
bioavailability of a drug payload.  We designed the PADNA system to sequester the 
antisense DNA drug Mipomersen[60] while circulating in the bloodstream, but to 
become activated after endosomal internalization. We created new, highly selective 
pH-switching DNA motifs to act as the gating system for Mipomersen release.  
Afterwards, we developed PGSA by modifying a previously published aptamer for 
Streptavidin with new pH-sensitive domains, where we can directly control the 
affinity of the aptamer for its target through modulation of the pH.  In the future, 
PGSA may be used to achieve pH-controlled activation of therapeutic aptamers at 
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specific stages of the endocytosis pathway, thereby acting as a next generation 
prodrug.   
The further development of PADNA and PGSA will involve modifications to 
allow these technologies to function in vivo as well as they have been 
demonstrated to work in vitro.  First, the most imminent need is to test how resistant 
PADNA and PGSA are to degradation by nucleases in blood and to add chemical 
modifications to the DNA that lengthen circulation time[124].  Second, PADNA and 
PGSA must be incorporated with a targeting moiety in order to deliver the drug 
payload to a specific tissue or cell type. Although optimization will be needed, in 
principle, targeting of the drug delivery vehicle can be achieved by conjugation with 
cell-surface targeting aptamers, peptides, and antibodies[125], [126].  Third, PADNA 
and PGSA must also be combined with a module to achieve endosomal escape.   
While PADNA and PGSA provide for pH-specific release inside the endosome, the 
payload may need transport to the cytosol to act upon a specific protein or 
organelle.  Currently, there are several well-established mechanisms to achieve 
endosomal escape including the proton sponge (inflow of water into the endosome 
causing rupture) and fusogenic peptides (fusion with endosomal membrane and 
lysis).  We can envision concatenation of PADNA and PGSA with one of these 
modules to provide transport into the cytoplasm. 
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6.2 Final comments on PMEDIC and Thermal Regeneration 
PMEDIC and the Thermal Regeneration Module were projects with the 
shared objective of creating an assay for endogenously secreted proteins in order 
to monitor the physiological status of a patient in real-time.  A device which provides 
continuous protein monitoring that is automated, requires no additional reagents 
and can be self-corrected for signal drift is highly advantageous.  Our contribution in 
PMEDIC and the Thermal Regeneration Module was to extend the useful lifetime of 
a single device.  We addressed the challenge of biofouling over time, ensured 
continuous microfluidic flow despite the formation of fibrin clots, and also developed 
a method to quickly regenerate the sensor for faster and more accurate 
measurements.   
While we have developed innovative supportive technologies which enable 
continuous operation of a single device (CDF, pretreatment cocktail, thermal 
regeneration), for our future work, we are considering alternative designs to achieve 
real-time monitoring.The biofouling phenomenon is a problem that scales with time 
and its degradative effects are not significant if sample incubation is less than 20 
minutes[48].  The need for continuous and smooth microfluidic flow presents an 
especially great challenge for monitoring coagulopathic blood, as its tendency to 
produce spontaneous clots in the sample line is unpredictable.  And perhaps most 
importantly, the continuous operation of the electrochemical sensor does not allow 
for a signal amplification step, limiting the sensitivity of our devices.  If we hope to 
someday achieve in vivo sensing of endogenously secreted proteins, we must 
develop a platform that can detect protein in the pM or lower range of 
concentration[105].   
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Going forward, we envision that continuous protein monitoring may be better 
achieved via an automated grid of single-use sensors.  Each miniature sensor 
would be programmed to automatically draw a microliter volume of blood, perform 
an amplification/sandwich-based assay, and then report the concentration.  After a 
specified period of time, the next sensor is activated to perform the same 
operations and the next data point is recorded.  Since each sensor is used only 
once and under static conditions, the requirements to protect the electrodes from 
biofouling and to ensure smooth microfluidic flow are obviated.  It also follows that 
sensor regeneration would not be needed.  Since it is relatively simple to fabricate 
small mini-sensors (~1 mm x 1 mm), we could easily package up to 100 tests into a 
single grid device employed at the bedside or perhaps even as a wearable device.  
An important consideration for our proposed design would be how to optimize the 
aptasensor self-assembly reaction to be uniform across all mini-sensors.  We would 
also plan to include a standard curve normalization step for all the mini-sensors in 
the array so that the data points produced by each sensor can be directly 
quantitatively compared. 
To conclude, whichever platform is eventually found to be most suitable for 
clinical implementation, there is no doubt that the future practice of medicine will 
rely on real-time diagnostics for better care. 
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6.3 Coda 
As medicine advances, controlled drug delivery will play an important role in 
increasing the efficacy of currently approved medications.  As the technology to 
control drug release increases in sophistication, it may be possible to revive 
previously unapproved drug candidates whose therapeutic window was too narrow 
for systemic administration, as currently evaluated by the FDA.  In the future, it is 
possible to envision that precisely targeted drug delivery combined with real-time 
diagnostics could allow for the safe application of drugs with narrow therapeutic 
windows, thus enabling patients to receive the benefit of a greater ensemble of 
pharmaceuticals[127].  Looking forward, advanced drug delivery vehicles will no 
doubt also be a significant aspect of developing next generation therapeutics which 
do not fit the classical pharmaceutical profile (small molecule, highly water soluble, 
permeable to the cell membrane)[22], [128].  High molecular weight biologicals, 
negatively charged gene therapies, and nanoparticle assemblies, for example, will 
require innovations in packaging to increase circulation time, target specific tissues, 
and increase cell uptake efficiency[128].  
Real-time diagnostics are likely to be a crucial tool in the future hospital 
environment, be it at the operating table or the bedside.   Being able to monitor the 
blood concentration during drug administration as well as the actual physiological 
response of the patient will enable a new practice of medicine that is more 
quantitative and data-rich.  Clinicians will be able to more accurately assess patient 
prognosis as well as react more quickly to adjust treatment.  Each patient may thus 
experience a better clinical outcome.  However, the significance of real-time 
molecular diagnostics extends beyond, to the patient population as a whole.  
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Importantly, the data gathered from real-time quantitative diagnostics will be more 
easily compiled and compared than phenomenonological observations, thus 
allowing for improved bioinformatics and statistical analysis.   As such, these data 
may be invaluable for future study into improving treatment for specific patient and 
disease populations. 
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